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I Introduction 
 
Cobalamin (vitamin B12) is a biologically active co-enzyme that is characterized as a 
water soluble, organometallic molecule with a planar corrin ring, surrounding a 
central cobalt atom (KOBAYASHI and SHIMIZU, 1999). Cobalamin can only be 
synthesized by certain fungi, actinomycetes, and a few species of bacteria (QURESHI 
et al., 1994). Cobalamin affects a wide variety of metabolic processes in many tissues 
and organs, including cell growth (HALL, 1979) and peripheral and central nervous 
system function (VOLKOV et al., 2006; SCALABRINO et al., 2000). Furthermore, 
cobalamin affects both the bone marrow (FYFE et al., 1991) and bone formation 
(TUCKER et al., 2005). Cobalamin deficiency has been reported to lead to 
hyperpigmentation and other effects in the skin (VOLKOV et al., 2006; 
BARTHELEMY et al., 1986) and the oral mucosa (FIELD et al., 1995). In humans, 
cobalamin deficiency can also lead to cardiovascular and thrombotic diseases, such as 
portal vein thrombosis (KANBAY et al., 2005; STANGER et al., 2003). 
 
Transport and metabolism of cobalamin are dependent on a number of different 
classes of proteins, which all can bind the cobalt atom. Intrinsic factor, 
transcobalamin I and II, membrane receptors, and intracellular binding proteins, such 
as methionine synthase or methylmalonyl-CoA mutase are examples of these proteins 
(QURESHI et al., 1994). There are two different cobalamin binding proteins in 
plasma, transcobalamin I and transcobalamin II, the former of which is present at 
higher concentrations (FOWLER, 1998). The latter is responsible for transport of 
cobalamin into cells by pinocytosis. Transcobalamin II is synthesized by amniocytes, 
fibroblasts, endothelial cells, and enterocytes, and is also present in cerebrospinal 
fluid, semen, and extracellular fluid (COOPER and ROSENBLATT, 1987). By virtue 
of the complex interaction of all these cobalamin binding proteins, many 
physiological functions of the body are affected by cobalamin. With cobalamin 
malabsorption, depletion of the cobalamin stores may therefore cause malfunction of 
multiple organ systems (VOLKOV et al., 2006). Inherited disorders of cobalamin 
homeostasis are commonly reported in humans and may affect absorption, transport, 
or cellular uptake of cobalamin (FOWLER, 1998). 
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It has been shown that some humans with juvenile cobalamin deficiency have a 
mutation of the gene encoding intrinsic factor (TANNER et al., 2005). Another group 
of patients characterized by an abnormally low serum cobalamin concentration and 
presenting signs suggestive of neurologic dysfunction, were found to have congenital 
transcobalamin II deficiency (CARMEL and RAVINDRANATH, 1984). In yet 
another group of patients, mutations of the cubilin and amnionless genes lead to 
cobalamin deficiency. These patients have Imerslund-Gräsbeck syndrome, which has 
been described in both humans and dogs (HE et al., 2003; FYFE et al., 1991a). 
Cubilin is part of the intestinal cobalamin receptor, which is located on the brush 
border membrane of ileal epithelial cells, and is responsible for endocytosis of 
intrinsic factor-cobalamin complexes (KOZYRAKI et al., 1999). Various defects of 
intracellular cobalamin deficiency have been reported in several different studies and 
have been designated as cobalamin deficiency type A to G. All these defects result in 
a deficient function of the two main cobalamin-dependant enzymes, methylmalonyl-
CoA mutase and methionine synthase (FOWLER, 1998). 
 
In dogs, selective intestinal cobalamin malabsorption has been reported in a family of 
Giant Schnauzers (FYFE et al., 1991a). Affected puppies started to show clinical 
signs of chronic inappetence and failure to thrive between 6 and 12 weeks of age, and 
were found to have neutropenia with hypersegmentation, anemia with anisocytosis 
and poikilocytosis, and megaloblastic changes of the bone marrow (FYFE et al., 
1991a). There has also been a case report of anemia due to cobalamin deficiency in a 
Border collie (MORGAN and MCCONNELL, 1999). The dog was found to have 
erythroblastic anemia, methylmalonic aciduria and low serum cobalamin 
concentration. Interestingly, these findings in these dogs of Giant Schnauzers were 
similar to the megaloblastic anemia, proteinuria, and low serum cobalamin 
concentrations seen in human patients with Imerslund-Gräsbeck syndrome 
(GRÄSBECK, 2006). Moreover, the so-called canine Imerslund-Gräsbeck syndrome 
has also been mapped to a region which is homologue to the human form (HE et al., 
2003). This syndrome in humans is associated with a selective cobalamin 
malabsorption by enterocytes, and is caused by a defect of the cobalamin receptor, the 
process of internalization of cobalamin-receptor complexes, or the transfer of 
cobalamin to transcobalamin II (HE et al., 2003; BURMAN et al., 1985). 
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Subnormal serum cobalamin concentrations in Shar Peis were first reported in a 
conference proceeding (WILLIAMS, 1991). In this report, 21 of 26 Shar Peis 
evaluated (80.8 %) had subnormal serum cobalamin concentrations. Nineteen of these 
21 dogs had serum cobalamin concentrations below the detection limit of the assay 
(WILLIAMS, 1991). These data suggested that disorders affecting the absorption of 
cobalamin are overrepresented in this breed (WILLIAMS, 1991). In addition, in 
another report, 89 of 139 (64.0 %) serum samples from Shar Peis that were submitted 
to the Gastrointestinal Laboratory at Texas A&M University between 2002 and 2006 
had serum cobalamin concentrations below the lower limit of the reference interval 
(252-908 ng/L) (BISHOP et al., 2007) and 53 of these 139 (38.1 %) serum samples 
had a serum cobalamin concentration below the detection limit of the assay (BISHOP 
et al., 2007). This study reported a significant difference between the serum 
cobalamin concentration in serum samples submitted from Shar Peis, when compared 
to samples from dogs of other breeds, including German Shepherd dogs, Labrador 
Retrievers, Boston Terriers, Yorkshire Terriers, Cocker Spaniels, and Beagles (p - 
value < 0.0001; Figure 1) (BISHOP et al., 2007). However, in the same study there 
was no statistically significant difference between the mean serum cobalamin 
concentration of Shar Peis and dogs of the above mentioned breeds, when samples 
that had results outside the reference interval were excluded from comparison (529.6 
ng/L and 500.7 ng/L, respectively; p = 0.9145) (BISHOP et al., 2007), suggesting that 
not all Shar Peis are affected by a putative genetic cause of cobalamin deficiency. 
 
Because of the increased incidence of cobalamin deficiency and the clinical signs 
previously described in Shar Peis with cobalamin deficiency (WILLIAMS 1991; 
PETERSON and WILLARD 2003), the objective of this study was to conduct a 
whole genome scan using the canine minimal screening set-2 (MSS-2) (CLARK et 
al., 2004) to identify linkage of a microsatellite marker with cobalamin deficiency in 
the Shar Pei. The MSS-2 is a set of microsatellite markers that has previously been 
used for whole genome scans in dogs with other diseases, including dermatomyositis 
in the Shetland Sheepdog (CLARK et al., 2005a), Collie Eye Anomaly (CEA) 
(LOWE et al., 2003), and pancreatic acinar atrophy (PAA) in the German Shepherd 
Dog (CLARK et al., 2005b). Except for the latter study, these whole genome scans 
pointed to a specific linkage of these diseases to a specific chromosomal region. 
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Figure 1: Comparison of the serum cobalamin concentration in dogs of different 
breeds. The serum cobalamin concentration in samples submitted from Shar Peis was 
significantly lower than in dogs of six other breeds (p-value < 0.0001) (BISHOP et 
al., 2007). 
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II Literature review 
 
1. Cobalamin (vitamin B12) 
 
1.1 Chemistry of cobalamin 
 
Cobalamin (vitamin B12) represents the most chemically complex vitamin. Karl 
Folkers and his coworkers first crystallized cobalamin in 1947 (RICKES et al., 1948). 
The three-dimensional structure was ascertained in 1956 by Hodgkin and coworkers 
(HODGKIN et al., 1956). 
 
Cobalamin is a water-soluble organometallic molecule with a planar corrin ring 
surrounding a central cobalt atom. The corrin contains four pyrrole rings in a planar 
formation, and as such is closely related to the porphyrin ring found in heme and 
cytochrome. However, with corrin, one pair of adjacent pyrrole rings are linked 
directly, while all four interpyrroline linkages in porphyrins are achieved through a 
carbon bridge (Figure 2) (HOGENKAMP, 1975; HUENNEKENS et al., 1982). 
 
Cobalamin contains cobalt as a centrally located metal ion, for which there are six 
coordination sites. Four of these are provided by the corrin ring, whereas the fifth is 
supplied by a dimethylbenzimidazole group. The sixth and last coordination site is 
variable, and the specific functional groups attached to the cobalt determine the type 
of cobalamin. Two of the resulting cobalamins, methylcobalamin (-CH3) and 5’-
deoxyadenosylcobalamin (5’-deoxyadenosyl-group), have coenzyme activity, and as 
such are biologically active. Other common functional groups yield cyano- (-CN), 
aquo- (-H2O), or hydroxocobalamin (-OH). The central cobalt atom exists in different 
oxidized forms. In cyano-, aquo-, and hydroxocobalamin the cobalt is in the oxidized 
3+ state, but cobalamin also occurs intracellularly with cobalt in the 2+ state and 1+ 
state, called cobalamin (2) and cobalamin (1). To date, the activities of other 
cobalamins, such as the glutathionylcobalamin complex and sulfitocobalamin, have 
not been intensively investigated. 
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Figure 2. Chemical structure of cobalamin. This figure displays the chemical 
structure of cobalamin with a planar corrin ring and the central cobalt atom (R= -CN, 
-H2O, -CH3, -OH, -5’-deoxyadenosyl-residue). (Modified from chemical structure of 
vitamin B12 (Azazell0); article: Symptoms of vitamin B12 deficiency by Val Tobin 
(June 6th 2010)). 
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1.2. Cobalamin sources 
 
Cobalamin cannot be synthesized by animals or plants, as only certain organisms have 
the enzymes required for the synthesis of cobalamin (BECK, 1982). The synthesis of 
cobalamin has first been described in detail by Woodward (WOODWARD, 1973) and 
Eschenmoser and colleagues (ESCHENMOSER and WINTNER, 1977). 
 
Cobalamin can be synthesized by certain fungi (Streptomyces griseus), actinomycetes 
(Streptomyces aureofaciens), and bacteria (Aerobacter spp., Agrobacterium spp., 
Alcaligenes spp., Azotobacter spp., Bacillus spp., Clostridium spp., Corynebacterium 
spp., Flavobacterium spp., Mycobacterium spp., Nocardia spp., Propionibacterium 
spp.,  Proteus spp., Pseudomonas spp., Rhizobium spp., Salmonella spp., Serratia 
spp., Streptococcus spp., and Xanthomonas spp.) (MARTENS et al., 2002; ROTH et 
al., 1996). The industrial production of cobalamin is achieved through fermentation of 
selected microorganisms, especially Pseudomonas denitrificans and 
Propionibacterium shermanii (DE BAETS et al., 2000; WATANABE, 2007). 
However, other microorganisms, such as Escherichia coli, Lactobacillus leichmanii, 
and yeast do not have the repertoire of enzymes to synthesize the corrin ring (BECK, 
1982; HERBERT, 1988). 
 
Humans, animals, and plants do not have the ability to synthesize cobalamin, but 
cobalamin can be absorbed from dietary sources. In general, dietary sources high in 
cobalamin include meat, dairy products, and fish (especially shellfish), whereas 
vegetables do not contain any significant amounts of dietary cobalamin (HERBERT, 
1988). 
 
Studies investigating the cobalamin concentration in various mammalian tissues 
revealed high concentrations of cobalamin in the kidneys and the liver, with a higher 
concentration in the liver compared to the kidneys (RETEY, 1982), indicating that the 
main storage of cobalamin in the body occurs in the liver (GLASS, 1959; 
BEEDHOLM-EBSEN et al., 2010). In humans, the half-clearance time of cobalamin 
from the body is several months (MARKLE, 1996). In cats, however, it has been 
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estimated that the half-clearance time of cobalamin is 12-13 days (SIMPSON et al., 
2001), whereas in dogs such data have not been reported. 
 
 
1.3 Absorption and transport of cobalamin 
 
The absorption of dietary vitamin B12 and its conversion to intracellularly active co-
enzyme is complex and involves many physiological processes, including gastric 
release of protein-bound cobalamin, intestinal uptake by a carrier-mediated transport 
process, intravascular transport, cellular uptake, intracellular release, and intracellular 
compartmentalization (HALL, 1979). The entire process of cobalamin absorption and 
transport depends on numerous proteins including intrinsic factor, R-binder, 
transcobalamin, cell membrane receptors, and intracellular binding proteins. 
 
Hanson characterized three main classes of cobalamin transport proteins (HANSEN, 
1990). Firstly, the large molecular size binder protein family, also known as R-
binders, comprises transcobalamin I, transcobalamin III, haptocorrin, and 
cobalophilins. R-binders are glycoproteins with a high affinity for cobalamin, and 
have been isolated from plasma, tissue extracts, secretions (e.g., saliva and bile), and 
the cytoplasm of erythrocytes, granulocytes, and platelets (FENTON and 
ROSENBERG, 1989; COOPER and ROSENBLATT, 1987). Following its ingestion, 
cobalamin is removed from dietary components and thought to bind to salivary and 
gastric R-binders (FENTON and ROSENBERG, 1989). Within the proximal 
duodenal lumen cobalamin is released from these R-binders by proteolytic enzymes 
from the pancreas. R-binders contain different amounts of carbohydrates and have 
different isoelectric points due to a variable sialic acid content. In humans different R-
binders in the systemic circulation bind about 80 % of the circulating cobalamin, 
albeit with a slow turnover (FRISBIE and CHANCE, 1993). 
 
Intrinsic factor, also known as S-binder, belongs to the second class of cobalamin 
transport proteins. Intrinsic factor is a glycoprotein that mediates the uptake of 
cobalamin from R-binders in the gastrointestinal tract. In humans intrinsic factor is 
produced exclusively by gastric parietal cells (FENTON and ROSENBERG, 1989), 
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whereas in dogs, intrinsic factor is mainly secreted from pancreatic acinar cells and to 
a smaller degree from the gastric mucosa (BATT et al., 1989; SIMPSON et al., 1993). 
While intrinsic factor binds cobalamin, it does not bind or mediate the uptake of 
cobalamin analogues, thereby minimizing their accumulation (SEETHARAM and 
ALPERS, 1985). Upon the binding of cobalamin, intrinsic factor molecules decrease 
in size, resulting in an increased affinity of the intrinsic factor-cobalamin complex for 
specific receptors located within the brush border membrane of ileal enterocytes 
(LEVINE et al., 1984; GUEANT et al., 2001). The process of cobalamin binding to 
intrinsic factor, the intrinsic factor-cobalamin receptor, as well as transcobalamin and 
R-binder, requires a neutral pH and the presence of Ca2+ ions (FEDOSOV et al., 
2002; ANDERSEN et al., 2010). 
 
Within the brush border membrane of the ileum, a specific receptor recognizes the 
intrinsic factor-cobalamin complex and allows for receptor-mediated endocytosis 
(FYFE et al., 2004). Thus, the intrinsic factor-cobalamin complex is crucial for the 
absorption of cobalamin via receptor-mediated endocytosis in the ileum (FYFE et al., 
2004). The intracellular release of cobalamin from intrinsic factor is presumed to be 
upon lysosomal digestion (ROTHENBERG and QUADROS, 1995). However, within 
the enterocytes cobalamin is never free and is bound either to intrinsic factor or to 
transcobalamin II (RAMANUJAN et al., 1991). The absorption of cobalamin from the 
enterocyte into the circulation is accomplished by passage of the basal membrane of 
the enterocytes, after which cobalamin is bound to transcobalamin II and enters the 
portal circulation. In humans, it has been reported that transcobalamin II is 
synthesized in the intestinal villi where the vascular endothelium is abundant 
(QUADROS et al., 1999). Transcobalamin II represents the third class of molecular 
cobalamin binders and is expressed by many additional tissues and body fluids 
(FENTON and ROSENBERG, 1989). More specifically, transcobalamin II is found in 
cerebrospinal fluid, plasma, semen, and extracellular fluids (COOPER and 
ROSENBLATT, 1987). It is also synthesized by amniocytes (ROSENBLATT et al., 
1987), fibroblasts (BERLINER and ROSENBERG, 1981), endothelial cells, and 
enterocytes (CHANARIN et al., 1978), as well as by the myocardium, kidneys, 
spleen, and several other tissues (FERNANDEZ-COSTA and METZ, 1982; HALL et 
al., 1984). Transcobalamin II binds only a small percentage (about 20 %) of the total 
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circulating cobalamin, but only transcobalamin II-cobalamin complexes can be 
internalized by peripheral tissues (SEETHARAM and ALPERS, 1985; ALLEN, 
1975). After binding of cobalamin, transcobalamin II undergoes a transformation that 
results in an increased affinity for its cellular membrane receptor. Comparable with 
the binding to intrinsic factor, this process also requires the presence of Ca2+ (NEXO 
and OLESEN, 1982; YOUNGDAHL-TURNER et al., 1978). After the binding of the 
transcobalamin II-cobalamin complex to its cellular membrane receptor the complex 
is absorbed by way of endocytosis. The transcobalamin II-cobalamin complex is 
degraded in the lysosome to yield free cobalamin, which is converted to 
methylcobalamin within the cytosol and/or to adenosylcobalamin inside the 
mitochondria. Cobalamin within the cell is bound to proteins, which are mainly 
cobalamin dependent enzymes such as methionine synthase and methylmalonyl-CoA 
mutase. 
 
In addition, two alternative mechanisms of cobalamin absorption have been reported 
in the literature (QURESHI et al., 1994). It has been shown in vitro that fibroblasts 
support the internalization of free cobalamin by use of a saturable and Ca2+ 
independent transport system with an electron transport chain across the membrane 
(BERLINER and ROSENBERG, 1981). Also, in humans, asialoglycoprotein 
receptors have been found in hepatocytes and enterocytes (MU et al., 1997; 
SEETHARAM and ALPERS, 1985). These hepatocytes with asialoglycoprotein 
receptors are able to clear cobalamin bound to R-protein from plasma and excrete it 
into the bile (SEETHARAM and ALPERS, 1985). 
 
Cobalamin is an essential co-factor for the cytoplasmic enzymes methionine synthase 
and methylmalonyl-CoA mutase, which bind more than 95 % of the intracellular 
cobalamin (MELLMAN et al., 1977; KOLHOUSE and ALLEN, 1977). The 
intracellular cobalamin undergoes a methylation to methylcobalamin, which 
represents the active form of cobalamin that is required for the conversion of 
homocysteine to methionine that is catalyzed by methionine synthase (FENTON and 
ROSENBERG, 1989). Methionine synthase requires the presents of the co-factor 
cobalamin as well as a methyl group. The methyl group is derived from the 
demethylation of 5-methyltetrahydrofolate that leads to its conversion to 
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tetrahydrofolate, which is the biologically active form of vitamin B9. 5-
Methyltetrahydrofolate, the monoglutamyl form of folate, is required for the re-
methylation of cobalamin and binds to methionine synthase. 5-Methyltetrahydrofolate 
is required for the purine and pyrimidine biosynthesis and is thus important for the de 
novo synthesis of DNA and RNA (Figure 3). Methylcobalamin is the major 
circulating form of cobalamin that is bound to transcobalamin I, and accounts for 60-
80 % of the total cobalamin in human plasma (FENTON and ROSENBERG, 1989). 
 
Methylmalonyl-CoA mutase, the second enzyme requiring cobalamin, catalyzes the 
final isomerization step in the metabolism of propionyl-CoA to succinyl-CoA in 
mammalian tissues (CANNATA et al., 1965; CHANDLER et al., 2006). Propionyl-
CoA results from beta oxidation of fatty acids. Propionyl-CoA also results from the 
catabolism of certain amino acids, such as valine, isoleucine, methionine, and 
threonine. Propionyl-CoA carboxylase and methylmalonyl-CoA racemase aid in the 
conversion of propionyl-CoA to D-methylmalonyl-CoA and further to L-
methylmalonyl-CoA. The subsequent conversion of L-methylmalonyl-CoA to 
succinyl-CoA can only occur when sufficient amounts of cobalamin are available 
within the cell. Thereafter, succinyl-CoA is being incorporated in the tricarboxylic 
acid cycle (Krebs’ cycle), which fuels the cellular energy (adenosine triphosphate 
(ATP)) production (Figure 4). Thus, in summary, cobalamin serves as an essential co-
factor for both methyl-CoA mutase and methionine synthase in mammalian cells. 
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Figure 3. Cobalamin represents an essential co-factor for intracellular 
methionine synthase: 
Methionine synthase is an enzyme that catalyzes the methylation of homocysteine to 
methionine. For this reaction to occur, methionine synthase requires the presence of 
the co-factor cobalamin as well as a methyl group, which is derived from the 
concurrent demethylation of 5-methyltetrahydrofolate to tetrahydrofolate, the 
biologically active form of vitamin B9, which is important for purine- and pyrimidine 
synthesis, and thus for the de novo synthesis of DNA and RNA. 
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Figure 4. Cobalamin is an essential co-factor for intracellular methylmalonyl- 
CoA mutase: 
Methylmalonyl-CoA mutase is an enzyme that catalyzes the conversion of L-
methylmalonyl-CoA to succinyl-CoA, for which it requires cobalamin as a co-factor. 
L-Methylmalonyl-CoA is a product of propionyl-CoA, which in turn is a product of 
the beta oxidation of fatty acids and the catabolism of certain amino acids. The 
conversion of L-methylmalonyl-CoA to succinyl-CoA is an essential step for the 
incorporation of these catabolic products into the tricarboxylic acid cycle. 
 
 
 
 
Literature review 
 
  
14 
 
2. Disorders of cobalamin absorption, transport and intracellular 
           metabolism 
 
2.1 Disorders of cobalamin absorption and transport 
 
The absorption of dietary vitamin B12 is complex and involves many steps, including 
gastric release of protein-bound cobalamin, intestinal uptake by a carrier-mediated 
transport process, intravascular transport, and cellular uptake. This process of 
cobalamin absorption and transport depends on numerous proteins including R-
binder, intrinsic factor, transcobalamin, and cell membrane receptors. However, 
disorders affecting the aforementioned proteins have been described in both the 
human and veterinary literature. 
 
 
2.1.1 R-binder deficiency 
 
There are only a few case reports of human patients with R-binder deficiency in 
plasma, saliva, and leukocytes (CARMEL et al., 2003). Affected individuals usually 
have a low serum cobalamin concentration, but no clinical signs of cobalamin 
deficiency. The reason for the lack of clinical signs of cobalamin deficiency in 
patients with R-binder deficiency is unclear. Also, serum concentrations of 
transcobalamin II have been reported to be within the reference interval in these 
patients (CARMEL, 1982). 
 
 
2.1.2 Intrinsic factor deficiency 
 
Humans with an inherited intrinsic factor deficiency show megaloblastic pernicious 
anemia, and have low serum cobalamin concentrations (SHEVELL and 
ROSENBLATT 1992). However, clinical signs of cobalamin deficiency are absent for 
the first few months of life, which might be due to an alternative pinocytic absorption 
mechanism for cobalamin, leading to an overall sufficient cobalamin transport  
(FENTON and ROSENBERG, 1989). The cause of the intrinsic factor deficiency has 
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been an area of intensive research. One suggested pathogenetic mechanism is an 
increased susceptibility of the intrinsic factor to proteolytic degradation (YANG et al., 
1985). 
 
 
2.1.3 Cobalamin malabsorption 
 
Imerslund-Gräsbeck syndrome in humans is a selective cobalamin malabsorption by 
enterocytes, and is caused by a defect of the cobalamin-intrinsic factor complex 
receptor, the internalization of cobalamin-receptor complexes, or the transfer of 
cobalamin to transcobalamin II (BURMAN et al., 1985; FYFE et al., 1991). About 60 
cases of this disease have been reported in humans, and the clinical findings in these 
patients include megaloblastic anemia, low serum cobalamin concentrations, and 
proteinuria (GRÄSBECK, 1972 and GRÄSBECK, 2006). Individuals with this 
disease develop clinical signs of cobalamin deficiency between 1 and 15 years of age. 
Imerslund-Gräsbeck syndrome is characterized by a normal transcobalamin II 
concentration, a normal intrinsic factor secretion and function, and a normal 
gastrointestinal morphology (COOPER and ROSENBLATT, 1987). Following 
cobalamin injection, these findings such as methylmalonic aciduria and low serum 
cobalamin concentration completely resolve, with the exception of persistent 
proteinuria. A similar syndrome of cobalamin malabsorption with an absence of ileal 
intrinsic factor-cobalamin complex receptors has also been described in a family of 
Giant Schnauzers, (FYFE et al., 1991a). It has been suggested that the receptor for 
intrinsic factor-cobalamin complexes is not being expressed in the brush border 
membrane of these dogs. 
 
 
2.1.4 Transcobalamin II deficiency 
 
Transcobalamin II deficiency in humans is generally characterized by megaloblastic 
anemia, vomiting, failure to thrive, pancytopenia, and eventually the development of 
immunologic and neurologic abnormalities (SHEVELL and ROSENBLATT, 1992). 
Usually, the symptoms start within the first two months of life. Transport of 
Literature review 
 
  
16 
 
cobalamin into the cells is hindered in the absence of transcobalamin II, but due to the 
presence of R-binder, which can resume some of the function of the missing 
transcobalamin, and that leads to a normal total circulating cobalamin concentration. 
However, the absorption of cobalamin is usually affected in these patients, suggesting 
an essentiality of transcobalamin II to enter the cells (COOPER and ROSENBLATT, 
1987; SEETHARAM and YAMMANI, 2003). 
 
 
2.2 Disorders of intracellular cobalamin metabolism 
 
2.2.1 Introduction 
 
In general, methylmalonic aciduria is a metabolic consequence of cobalamin 
deficiency and is characterized by an accumulation of large amounts of 
methylmalonic acid (MMA) in serum, and as a result, excretion of MMA in the urine 
of affected individuals (COOPER and ROSENBLATT, 1987; FENTON and 
ROSENBERG, 1978). This is caused by an intracellular failure of the conversion of 
methylmalonyl-CoA to succinyl-CoA and the accumulation of the metabolite 
methylmalonic acid in the blood, which in turn is excreted in the urine and can be 
used as a marker for cobalamin deficiency at the cellular level (Figure 5). In healthy 
animals, small amounts of methylmalonic acid are found in the blood, urine, and 
cerebrospinal fluid. 
 
In humans and dogs with methylmalonic aciduria the characteristic laboratory 
findings include secondary hyperammonemia, which is caused by an accumulation of 
propionyl-CoA, hypoglycemia, which is due to an impaired mitochondrial transport of 
glucose phosphate, and increased concentrations of ketones and methylmalonic acid 
in the urine (COOPER and ROSENBLATT, 1987; FYFE et al., 1991). In human 
patients, response to parenteral administration of cobalamin is variable. Patients that 
respond to cobalamin supplementation have been shown to be affected with 
cobalamin deficiency that only affects the synthesis of adenosylcobalamin in 
fibroblasts, whereas in individuals that did not respond to cobalamin injections, the 
synthesis of methylmalonyl-CoA mutase has been demonstrated to be affected. This 
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difference suggests that different intracellular forms of cobalamin deficiency can lead 
to methylmalonic aciduria. 
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Figure 5. This figure shows the cause of methylmalonic acid accumulation in patients 
with cobalamin deficiency. A lack of cobalamin leads to a failure to convert L-
methylmalonyl-CoA to succinyl-CoA. In turn some L-methylmalonyl-CoA is 
converted to D-methylmalonyl-CoA (enzyme: methylmalonyl-CoA mutase), which in 
turn is converted to methylmalonic acid (enzyme: methylmalonyl-CoA hydroxylase). 
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2.2.2 Metabolic consequences of cobalamin deficiency - Cobalamin A to G   
           diseases 
 
Biochemical studies have described human patients with selective or combined 
deficiencies of adenosylcobalamin and methylcobalamin, and those with selective or 
combined deficiencies have been characterized in cultured skin fibroblasts using 
different methods such as the conversion of propionate to succinate to evaluate the 
existence of the intermediary enzyme methylmalonyl CoA mutase and to assess the 
cellular uptake of cobalamin and its conversion to active coenzymes with the aid of a 
specific cobalamin adenosyltransferase assay (FENTON and ROSENBERG, 1978). 
Patients with such selective or combined deficiencies have been grouped into 7 
independent groups: cobalamin A to cobalamin G disease, which provide insights into 
the pathway of intracellular cobalamin transport (GRAVEL et al., 1975; WILLARD 
et al., 1978; SHEVELL and ROSENBLATT, 1992). 
 
Cobalamin A and cobalamin B disease are characterized by a deficient activity of L-
methylmalonyl-CoA mutase, which is caused by the deficiency of that cobalamin-
dependent enzyme and which leads to methylmalonic aciduria (COOPER and 
ROSENBLATT, 1987). Human patients with cobalamin A disease have a selective 
deficiency of adenosylcobalamin, but have normal concentrations of methylcobalamin 
intracellularly and no homocysteinuria (COOPER and ROSENBLATT, 1987). In cell 
extracts from patients with cobalamin A disease usually have a normal 
adenosylcobalamin synthesis and a decreased accumulation of adenosylcobalamin in 
intact fibroblasts due to the non-enzymatic reduction of cobalamin (2) to cobalamin 
(1) followed by the synthesis of adenosylcobalamin (WILLARD et al., 1978; 
MAHONEY et al., 1975). In contrast, cell extracts and intact fibroblasts from patients 
with cobalamin B disease were shown to lack adenosylcobalamin, indicating normal 
cobalamin reduction but a deficiency in cobalamin I ATP-adenosyltransferase 
(FENTON and ROSENBERG, 1981). Approximately 90 % of patients with 
cobalamin A disease, but less than 40 % of patients with cobalamin B disease respond 
to supplementation with cobalamin, indicating a good prognosis for patients with 
cobalamin A disease compared to those with cobalamin B disease (MATSUI et al., 
1983). Finally, a few years ago, the genes responsible for both cobalamin A and 
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cobalamin B disease in humans have been identified (DOBSON et al., 2002; 
DOBSON et al., 2002). 
 
Cobalamin C and cobalamin D disease are associated with a decreased synthesis of 
adenosylcobalamin and methylcobalamin, resulting in both methylmalonic aciduria 
and homocystinuria (ROSENBLATT and COOPER, 1987). However, serum 
concentrations of cobalamin are usually within the respective reference intervals 
because affected patients have normal intestinal absorption and vascular transport of 
cobalamin leading to a normal total circulating cobalamin concentration 
(ROSENBERG and FENTON, 1989). Cobalamin C disease has been reported in more 
than 75 humans and has been suggested to be an inherited disorder (ASPLER et al., 
1993; PLETCHER et al., 1991). Symptoms of cobalamin C disease become evident 
within the first year of life or during adolescence (SHINNAR und SINGER, 1984). 
The clinical findings in human patients usually are a failure to thrive, lethargy, 
inappetence, developmental delay, microcephaly, seizures, hypotonia, and 
hypomethioninemia (COOPER and ROSENBLATT, 1987). Furthermore, hemolytic 
uremic syndrome (GERAGHTY et al., 1992), hepatic dysfunction (CAOUETTE et 
al., 1992), and hydrocephalus (PLETCHER et al., 1991) have been documented in 
these patients. Cobalamin D disease has been demonstrated in two siblings with 
different clinical pictures (WILLARD et al., 1978). One of the patients was 
asymptomatic, whereas the older brother of that patient had mental and behavioral 
abnormalities (GOODMAN et al., 1970). Intracellular cobalamin in fibroblasts from 
patients with cobalamin D disease were unaffected by cyanocobalamin in the culture 
medium, indicating an inability to exchange the cyanide group for a hydroxyl group. 
The ability to exchange the cyanide group for a hydroxyl group can be used to 
distinguish patients with cobalamin C disease from those with cobalamin D disease 
(MELLMAN et al., 1978). Different studies have shown that cobalamin D disease is 
similar to cobalamin C disease, but it is associated with less severe abnormalities 
compared to those found in patients with cobalamin C disease. 
 
A few patients have been described as having cobalamin F disease. One of the cases 
reported represented an infant with developmental delay, cobalamin responsive 
methylmalonic aciduria, but no indication of megaloblastic anemia or 
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homocysteinuria (ROSENBLATT et al., 1986; ROSENBLATT et al., 1985). In this 
case a Schilling test revealed a decrease in cobalamin absorption (LAFRAMBOISE et 
al., 1992). A Schilling test can be used to evaluate the ability of a human patient to 
absorb cobalamin. This test measures the uptake of orally administered 57Co- or 58Co-
labeled cobalamin following the saturation of the cobalamin receptors in the liver by 
an intramuscular injection of cobalamin. The latter ensures that the majority of orally 
given cobalamin circumvents the liver and is being cleared from the circulation by the 
kidneys. Thus, the radioactivity measured in a urine sample within 24 hours after oral 
cobalamin supplementation theoretically reflects the amount of cobalamin absorbed 
from the gastrointestinal lumen. This value should be at least 5 % in a human patient 
with normal cobalamin absorption. 
Another patient, 11 years of age, presented with pancytopenia, an increased 
erythrocyte mean corpuscular volume, a decreased serum cobalamin concentration, an 
abnormal Schilling test, and methylmalonic aciduria. Intracellular 
methyltetrahydrofolate was decreased in patients with cobalamin F disease 
(ROSENBLATT et al., 1986). Incubation of fibroblasts obtained from patients with 
cobalamin F disease with cyanocobalamin yielded no synthesis of either 
adenosylcobalamin or methylcobalamin but an abnormal accumulation of free 
cobalamin within the lysosomes and no megaloblastic anemia or homocystinuria 
(VASSILIADIS et al., 1991). However, the internalization of cobalamin bound to 
transcobalamin II was unchanged in cells from patients with cobalamin F disease 
(ROSENBLATT et al., 1985). Therefore, the defect in patients with cobalamin F 
disease has been suggested to affect the release of lysosomal cobalamin into the 
cytoplasm (ROSENBLATT, 1992). 
 
Cobalamin E and cobalamin G diseases are characterized by a failure of methionine 
biosynthesis and the accumulation of homocysteine in the urine. In patients with 
cobalamin E or cobalamin G disease, serum cobalamin and folate concentrations are 
usually within the reference interval (FENTON and ROSENBERG, 1989). Patients 
usually present with homocysteinemia and hypomethioninemia, but not with 
methylmalonic aciduria (COOPER and ROSENBLATT, 1987; ROSENBLATT and 
COOPER, 1989; WATKINS and ROSENBLATT, 1989). Surprisingly, one patient 
with cobalamin E disease presented with transient methylmalonic aciduria 
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(TUCHMAN et al., 1988). Two types of cobalamin G disease have been reported, 
which are differentiated based on a normal or reduced activity of methionine synthase 
in cell extracts (WATKINS and ROSENBLATT, 1989). In most cases, the disease 
presents itself within the first year of life, but it has also been diagnosed in a 21 year 
old patient (CARMEL et al., 1988). Cobalamin E and cobalamin G disease both 
represent a heterogeneous group of patients characterized by a functional methionine 
synthase deficiency due to a decreased methionine biosynthesis, leading to decreased 
intracellular concentrations of methylcobalamin (ROSENBLATT, 1992; 
ROSENBLATT et al., 1984). 
 
 
2.2.3 Methylmalonyl-CoA disease 
 
This disorder is characterized by a defect of the mitochondrial enzyme 
methylmalonyl-CoA mutase. This enzyme catalyzes the isomerization of 
methylmalonyl-CoA to succinyl-CoA and thus is crucial for the metabolism of odd-
chain fatty acids, cholesterol, and branched-chain amino acids to enter the 
tricarboxylic acid cycle in mammals (BANERJEE, 2003). The defect of 
methylmalonyl-CoA mutase is characterized by the presence of methylmalonyl 
aciduria in the absence of homocysteinuria. Also, methylmalonyl aciduria does not 
resolve upon supplementation with cobalamin. Two different mutant cell lines have 
been described that lead to this disease (WILLARD and ROSENBERG, 1980). 
Patients with one of the mutant cell lines showed a detectable methylmalonyl-CoA 
mutase activity in cell extracts. This was demonstrated by an increased ability to 
utilize propionate after supplementation with hydroxocobalamin. This mutant cell line 
was termed mut¯. In contrast, the second mutant cell line showed an undetectable 
mutase activity in cell extracts after hydroxocobalamin supplementation and this 
mutant cell line was termed mut0. A genetic test has been developed to identify 
patients with either the mut¯ or mut0 genotypes, and to differentiate them from 
patients with other causes of cobalamin deficiency (WILKEMEYER et al., 1991). 
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3. Canine Genetics 
 
3.1 Introduction 
 
During the last decade, the domestic dog, Canis lupus familiaris, has frequently been 
used as a model for the study of hereditary diseases and gene expression in humans. 
The dog is believed to be the oldest domesticated animal species. All the species 
related to the domestic dog such as coyotes, jackals, and various wolves, are 
phylogenetically closely related and are thus capable of interbreeding (WAYNE and 
OSTRANDER, 1999). It has been suggested that the large phenotypic diversity within 
the dog species represents the result of multiple founding species believed to have all 
diverged from the wolf (Canis lupus). Different studies revealed that the domestic dog 
is related to the Chinese Wolf (WAYNE and OSTRANDER, 1999) as well as to 
wolves of East Asian origin (SAVOLAINEN et al., 2002). Results of one study 
pointed to a single domestication event that would have occurred roughly 15,000 
years ago (SAVOLAINEN et al., 2002). Selective breeding by humans over the last 
centuries has created more than 300 different dog breeds with a clear number of genes 
that are uniquely characteristic for each breed. These dog breeds represent isolated, 
inbred populations as most of them have developed more than 250 years ago 
(OSTRANDER and GINIGER, 1999). Therefore, these breeds demonstrate genotypic 
and phenotypic homogeneity, giving rise to founder effects and population 
bottlenecks. One effect of such breeding practices appears to be the large number of 
genetic diseases described in dogs. Approximately 450 hereditary diseases have been 
described in dogs in the Online Mendelian Inheritance in Animals database (OMIA 
2003). Many of these diseases resemble clinical syndromes similar to hereditary 
diseases in humans, and some even share the mutation of a gene that is responsible for 
the disease (OSTRANDER and GINIGER, 1997; OMIA 2003). These spontaneous 
mutations in the dog offer the possibility to study canine spontaneous diseases as a 
model of human diseases (KIJAS et al., 2002). 
 
It has previously been shown that the 1.5X coverage of the canine genome sequence 
(with 6.22 million sequence reads) indicate that the dog and human genome 
sequences are more similar to each other when compared to the mouse genome 
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sequence (KIRKNESS and BAFNA, 2003). The canine genome was sequenced inter 
alia by the National Human Genome Research Institute. One aim of this project was 
to understand the genetics of hereditary diseases in dogs. One further advantage of 
studying dogs is that the inter-individual variation in dogs is lower than that in 
humans, mice, or rats, but similar to that of other domesticated animals (ZAJC et al., 
1997). Therefore, the dog was selected as a superior model for genome sequencing 
instead of some other species such as mice or rats. 
 
In general, the term linkage disequilibrium is defined as a non-random association of 
alleles of two or more loci. Those alleles can be located on the same chromosome, but 
this is not always the case. Linkage disequilibrium depicts a situation in which allele 
combinations or genetic markers occur more or less frequently in a population. A 
genetic association is dependent upon the respective population, and linkage 
disequilibrium can extend from 400 to 700 kb in popular dog breeds (e.g., German 
Shepherd dogs, Labrador Retrievers), whereas it can range from 3 to 3.2 Mb in dog 
breeds with a smaller population size such as the Shar Pei (SUTTER et al., 2004; 
GUYON, 2003). In the United States, for instance, Shar Peis appear to be a rare 
breed, ranked 47th by the American Kennel Club in 2009 (compared for example to 
position 3 for the German Shepherd dog) (http://www.akc.org/reg/dogreg_stats.cfm; 
accessed June 29th, 2010). 
 
 
3.2 Genomic Map 
 
Over the last decade, various maps of the canine genome have been established. 
Mellersh and colleagues published the first linkage map for dogs in 1997, which at 
that time included 139 microsatellite markers and 30 linkage groups (MELLERSH 
and LANGSTON, 1997). Two years later, a specific canine (donor) -rodent (recipient) 
cell line was used to construct a canine radiation hybrid map (VIGNAUX et al., 
1999). That panel comprised 218 markers for genes and 182 microsatellite markers 
(VIGNAUX et al., 1999). In 2001, Breen and colleagues constructed an integrated 
linkage-radiation hybrid map of the canine genome (BREEN et al., 2001). These 
maps and the identified microsatellite markers have been designed for whole genome 
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scan studies. Ideally, the microsatellite markers should be spread out evenly across all 
chromosomes. Also, polymorphic information content (PIC) values, which can range 
from 0.0 (not informative) to 1.0 (very informative), should be considered to 
determine how informative each of the markers are for an association study. 
 
The first microsatellite marker set that provided coverage of the canine genome was 
published by Richman in 2001. This set, called the Minimal Screening Set-1 (MSS-1), 
comprised 172 microsatellite markers, of which 64 were di-, 3 were tri-, and 104 were 
tetrameric nucleotide markers with an average polymorphic information content (PIC) 
value of 0.74 (RICHMAN et al., 2001). The MSS-1 had an average spacing of the 
markers of 10 cM with gaps between markers no greater than 20 cM (RICHMAN et 
al., 2001). Two years later, an updated radiation hybrid map was published containing 
a data for 3,270 markers. The distance between these markers was reduced to about 1 
Mb (GUYON et al., 2003). This panel represented a more comprehensive screening 
set than the Minimal Screening Set-2 (MSS-2), which was developed by Clark et al. 
also for conducting genome-wide scans (CLARK et al., 2004b). A total of 327 
microsatellite markers were contained in the MSS-2, and the average spacing was 9 
Mb with no gaps larger than 17.1 Mb (Clark et al., 2004b; GUYON, 2003). The 
nucleotide repeats were distributed as follows: 151 di-, 3 tri-, and 171 tetramers with 
an average polymorphic information content (PIC) value of 0.73 (Table 1.). It should 
be noted that one-sixth of the microsatellite markers of the MSS-1 were also 
contained in the MSS-2 (RICHMAN et al., 2001; CLARK et al., 2004b). 
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Table 1. Chromosome-specific microsatellite multiplex set (MSS-2) 
 
Chromosome/ 
Multiplex (1) 
Marker 
(2) 
Primer 
volume (3) 
Fluorescent 
label (4) 
 
Chromosome/ 
Multiplex (1)  
Marker 
(2) 
Primer 
volume (3) 
Fluorescent 
label (4) 
1.1  FH3413 0.8 P  6.1 FH2525  0.8 V 
 REN112I02 0.8 V   FH2561  1.4 N 
 C01.424  0.8 F   FH2734  0.8 V 
 C00901  0.8 P   FH2164 0.8 V 
 FH2793 0.6 P    FH3303  0.5 P 
 FH2326  1.0 N  6.2 FH2576   0.6 F 
1.2 FH3325  0.8 P   FH3933 0.8 P 
 FH3300  0.8 N   FH2370  0.8 N 
 C01.251  0.8 N  6.3 REN285H12  0.8 F 
 FH2309  0.8 V   FH2119  0.8 N 
 REN143K19  0.6 V   REN111L07  0.8 P 
1.3 FH2663  1.1 F  7.1 REN97M11   0.8 P 
 FH3603 1.5 F   FH3972 0.6 N 
 FH3922  1.1 F   REN162C04  0.8 V 
 FH2294 0.3 N   REN143L20  0.6 P 
2.1 FH3210 0.8 P   FH2860  0.4 V 
 REN303H07  0.8 V  7.2 FH2226  0.8 N 
 REN70M14  0.8 V   VIASD10  0.8 P 
 FH3965 0.8 F   FH2973 0.8 P 
2.2 FH2890  0.4 N  8.1 FH3241  0.8 P 
 C02.609  0.6 P   REN204K13  0.8 N 
 FH2613  0.6 V   FH3316   0.8 V 
 FH2132  0.6 F   C08.618  0.8 F 
2.3 FH2274 0.8 N  8.2 FH3425   0.8 N 
 FH2608 0.8 P   C08.410  0.8 F 
 C02.342  0.8 F   REN178J05  0.6 F 
3.1 REN161A12  0.6 F   FH2989  1.0 V 
  FH3252  0.6 P  9.1 GALK1  0.6 V 
 FH3464  0.6 V   FH2263  0.8 N 
 FH2316 0.8 N   C09.173  0.4 N 
 FH3377  0.6 N   REN54L20  0.4 F 
3.2 FH3115 0.8 N   G06401   0.6 P 
 C03.629  1.2 V   REN287G01  0.6 N 
 FH2145  0.8 P  9.2 FH2186  1.4 V 
 REN260I04  0.6 F   REN145P07  0.6 P 
3.3 FH3396  1.0 F   FH3835   0.3 F 
 FH2302  0.6 V   REN73K24  0.3 V 
4.1 REN298N18 0.4 P   FH2885  0.4 N 
 REN303C04  0.4 V  10.1 FH2537  0.8 N 
 FH2732 0.8 F   FH4081  0.8 P 
 FH3310  0.8 F   C10.781  0.6 V 
 REN74B13 0.6 V    ZUBECA1  0.4 N 
 AHT103  0.8 F   DTR10.5   0.8 F 
4.2 FH2776  1.0 P   FH3381   0.8 P 
 REN195B08  0.8 N  10.2 REN06H21  0.8 P 
 FH2097 0.6 N   FH2293  0.8 V 
 G07704  0.6 V   C10.16  0.8 F 
5.1 FH3004 0.8 F   FH2422  0.8 N 
 DTR05.8  0.8 N  11.1 FH3203   0.8 V 
 FH3978 1.0 P   REN242K04  0.8 F 
 REN175P10 0.6 V   FH2004  0.6 F 
 CPH14 0.8 N   C11.868  0.8 P 
5.2 FH3928  0.8 P   C11.873  0.8 V 
 FH3320 0.6 N   DGN13  0.8 V 
 FH3702  0.8 F  11.2 AHT137  0.3 V 
 FH3089  0.8 V   FH4031  0.8 P 
5.3 FH2140   0.8 P   FH2319   1.0 N 
 REN285I23  0.8 V   FH2019  0.2 N 
 FH3278 0.8 P      
 C05.771  0.6 V      
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Table 1 – continued: Chromosome – specific microsatellite multiplex set (MSS-2) 
 
Chromosome/ 
Multiplex (1) 
Marker 
(2) 
Primer 
volume (3) 
Fluorescent 
label (4) 
 
Chromosome/ 
Multiplex (1)  
Marker 
(2) 
Primer 
volume (3) 
Fluorescent 
label (4) 
12.1 REN153O12  0.6 F  19.1 REN213G21  0.6 V 
 FH2401  0.6 V   FH3491  0.4 F 
 FH3591  0.6 N   FH3313  1.0 P 
 G01811  0.6 P   FH2206  0.8 P 
 REN94K11  0.6 N   FH2380  0.6 N 
12.2 REN258L11   0.8 P  19.2 FH3299   0.6 V 
 REN213F01  0.8 F   FH3834 0.6 F 
 FH3711  0.8 N   FH3969  0.6 N 
 FH1040  0.6 V  20.1 PEZ19  0.8 N 
 FH3748  0.8 P   FH2951  0.6 F 
13.1 C13.391  0.8 N   FH2158  1.0 P 
 REN120P21  0.6 F   REN114M19  0.4 F 
 FH3619  0.6 P  20.2 REN55P21  0.8 N 
 DTR13.6  0.6 F   REN100J13  0.8 P 
 FH2348   1.2 V   REN93E07  0.2 V 
 FH3800  0.6 N   AHTk209  1.0 N 
 FH3494  0.8 V  21.1 FH3803   1.0 P 
 REN227M12  0.8 P   FH2233  0.8 F 
14.1 FH3951  1.0 F   REN118B15  0.3 V 
 FH3725  0.6 P   FH2441  0.8 N 
 FH2658  1.0 P   REN37A15  0.3 V 
 FH2763 0.4 N   FH3398 0.8 P 
14.2 C14.866  0.8 F   FH2312 0.8 N 
 FH3285  0.8 P  22.1 REN42F10  0.8 V 
 PEZ10  0.8 V    FH3355  0.8 V 
15.1 FH4012  0.6 P   FH3411  0.8 N 
 FH3813  0.8 V   FH3853  0.8 P 
 FH2171 0.6 N  22.2 REN49F22  1.0 N 
 CPH4  0.8 N   REN128E21 1.0 P 
 REN230G12 0.6 F   C22.279  0.4 V 
15.2 FH3802  0.6 V   REN78I16  0.6 F 
 REN06C11  0.6 F  23.1 FH3078  0.8 P 
 FH2360  0.8 P   FH2508 1.0 P 
16.1 REN214L11  0.4 V   REN181K04 0.8 P 
 FH2670  0.6 F   REN113M13  0.6 V 
 REN73O19  0.6 P   REN02P03 0.8 N 
 REN85N14  0.8 P   FH2626  0.8 F 
 FH3592  0.8 V  24.1 FH3023  0.8 P 
16.2 FH2155  1.0 N   FH2261  0.8 F 
 REN275L19  0.4 N   AHT125  0.8 P 
 FH2175  1.2 F   FH3287  0.8 F 
17.1 REN240A05  0.6 F   REN228J19  0.8 V 
 FH3369  0.6 P  24.2 FH3750   0.8 P 
 REN294E18  0.6 V   FH2159  0.8 N 
 FH3995  0.8 F   REN106I06   0.6 V 
17.2 FH3047   0.8 P    REN272I16  0.4 F 
 FH4023  0.8 P  25.1 REN54E19   0.8 F 
 PEZ8  1.0 N   FH3245 0.8 P 
 FH2869  0.6 V   FH2324   0.3 N 
18.1 FH4060  1.0 N   FH2141  1.0 N 
 FH3944  0.8 P   FH3627 0.3 V 
 FH3824  0.4 V   FH4027  0.7 F 
 FH3815  0.4 F  26.1 REN62M06  0.4 N 
 REN54P11 0.8 P   DTR26.9  0.4 V 
 FH2834  0.4 N   FH3426   0.4 V 
 REN47J11 0.8 V   DGN10  0.8 P 
 AHT130  0.6 F   FH2130  1.0 N 
      C26.733  0.6 F 
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Table 1 – continued: Chromosome – specific microsatellite multiplex set (MSS-2) 
 
Chromosome/ 
Multiplex (1)  
Marker 
(2) 
Primer 
volume (3) 
Fluorescent 
label (4) 
 
Chromosome/ 
Multiplex (1)  
Marker 
(2) 
Primer 
volume (3) 
Fluorescent 
label (4) 
27.1 FH3221  0.8 P  34.1 FH3721  0.8 P 
 PEZ6  0.6 F   REN174M24  0.6 F 
 REN181L14  0.4 N   REN243O23  0.8 F 
 REN72K15  0.4 V   REN314H10  0.4 V 
27.2 FH2289   0.8 P  34.2 REN109L16  0.8 N 
 PEZ16  0.3 N   FH2377  0.8 V 
 LEI002  0.3 F   FH3836  0.8 N 
 FH3924  0.6 V  35.1 FH3570  0.8 F 
28.1 C28.176   0.8 V   REN282I22  0.4 V 
 FH3963  0.8 P   REN94K23  0.6 N 
 FH2585  0.8 F   REN112C08  0.6 P 
 REN146G17  0.8 V  36.1 REN106I07   0.8 V 
 FH2208 0.8 N   FH2611 0.8 P 
29.1 FH2952  0.8 P   REN179H15  0.8 P 
 FH2364  0.8 F   FH3865  0.8 V 
 REN52D08  0.4 P   DTR36.3  0.8 N 
 REN45F03  0.8 F  37.1 FH3272 0.8 F 
 FH2385  1.0 V   H10101  0.8 V 
 FH1007 0.3 V   REN67C18   0.8 P 
30.1 FH3489  0.4 F   FH3449  0.8 F 
 REN51C16  0.4 P   FH2532 0.8 N 
 REN248F14  0.8 V  38.1 FH2766   0.8 P 
 FH2290  1.0 N   REN02C20  0.8 F 
 FH3632  0.8 P   REN164E17  0.8 N 
 FH3053  0.4 F  X.1 FH2916  0.8 F 
31.1 FH2189   0.8 N   REN101G16  1.0 N 
 RVC11  0.6 V   D04614   0.8 F 
 REN43H24   0.6 N   REN144O22 0.6 V 
 REN109B10  1.2 P  X.2 FH3027   0.8 N 
 REN110K04  0.8 P   FH1020  0.8 F 
 FH2712  0.4 F   FH2985   0.6 N 
32.1 REN244E04  0.3 F   REN230I20  0.6 V 
 CPH2  0.4 V  X.3 REN130F03  0.8 F 
 FH2875  0.6 N   FH2584  0.8 N 
 FH3635  1.0 F   REN75A05  0.8 P 
 FH3236  0.8 N  Y.1 REN197E16  0.8 V 
 AHT127 0.3 V   REN44K10  0.6 F 
 FH3294  0.8 P   DTRY.13  0.4 F 
33.1 FH2790   0.4 F   REN75H09  0.2 V 
 FH3608  0.8 F   REN173O16 0.2 P 
 FH2361  0.3 V      
 REN186B12  0.6 V      
 FH2165  0.8 N      
 
 
Table 1. This table represents all microsatellite markers (chromosome 1 to Y) of the 
canine Minimal Screening Set-2 (MSS-2). Column (1) lists the chromosome and 
multiplex set number within the respective chromosome. Column (2) shows each 
microsatellite marker. Column (3) represents the volume (in µl) of each forward and 
reverse primer used for the multiplex PCR. Column (4) lists the fluorescent label (F = 
6FAM, P = PET, V = VIC, N = NED) used for the respective marker. 
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3.3 Linkage analysis 
 
The unique population structure of the dog lends itself to the study of human 
hereditary diseases, but it should be pointed out that there are many diseases unique to 
the dogs. However, due to the role of the dog in our society as a guardian and 
companion, it would also be worthwhile to eliminate specific hereditary diseases of 
the dog. It has been reported that about two-thirds of hereditary diseases in dogs are 
transmitted by autosomal recessive traits (OSTRANDER and KRUGLYAK, 2000). 
Therefore, elimination of the respective alleles represents a challenge for breeder 
clubs and breeders. 
 
With hereditary diseases the clinical symptoms can occur in either young or older 
dogs, which should be considered for planning association studies. Linkage analysis is 
aimed at the identification of markers that associate with a particular disease, which 
allows for subsequent development of a PCR-based test to identify potential carriers 
and affected animals prior to the onset of clinical signs. 
 
 
3.4 Linkage analysis strategies 
 
Causative disease factors may be investigated using two different approaches. Many 
diseases in dogs have a significant genetic basis, and one commonly used technique to 
identify genetic risk factors for complex disorders is the candidate gene approach, 
which directly tests the effects of genetic variants of a potentially contributing gene in 
an association study. The candidate gene approach is used where genes are known 
that control the physiologic function that is affected in diseased patients. These 
candidate genes are usually chosen based on known mutations in similar syndromes in 
different species or genes that code for proteins that might play an important role in 
the disease process of interest. However, there are diseases where the underlying 
disease process does not allow for the selection of a suitable candidate gene and a 
genome wide scan is needed. For instance, cobalamin deficiency in the Shar Pei has 
not shown any similarities to human patients with symptoms of hereditary cobalamin 
deficiency or similar conditions in veterinary patients (FYFE et al., 1991a; CARMEL, 
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2000; FORDYCE et al., 2000). The lack of the classical signs of cobalamin deficiency 
suggests that other unknown mechanisms may be responsible for this condition in 
Shar Peis. Thus, instead of a candidate gene approach, recombination mapping 
strategies, such as classical linkage analysis and linkage disequilibrium analysis, are 
warranted. Classical linkage studies are used to trace inheritance through the pedigree 
of a family. Linkage disequilibrium has been suggested for small numbers of 
unrelated and purebred dogs (HYUN et al., 2003). However, both the candidate gene 
approach and genome wide scan require the construction of pedigrees. 
 
 
3.5 Multiplex-PCR based approach 
 
Microsatellite markers have proven to be a valuable tool for linkage analysis, linkage 
disequilibrium, and forensic investigations in the dog (LEOPOLDINO and PENA, 
2003). Microsatellite markers can also be used for the identification of individuals as 
well as the determination of parentage (such as relationship and haplotype estimation) 
of a specific breed as well as between breeds (SUTTON et al., 1998; ZAJC and 
SAMPSON, 1999; MULLER et al., 1999; CLARK et al., 2004a). 
 
Microsatellite profile “genotyping” requires the availability of genomic DNA and an 
optimized PCR in order to allow for the accurate determination of genotypes. As it 
would be costly and time consuming to evaluate each single microsatellite marker 
contained in a microsatellite marker set through a separate PCR reaction, a multiplex 
PCR suitable for linkage studies has been developed for humans (BEEKMAN et al., 
2001), but also for forensic investigations for several other mammals including the 
dog (KOSKINEN und BREDBACKA, 1999; ALTET et al., 2001; CLARK et al., 
2004a). Thus, a multiplex PCR approach for a set of selected microsatellite markers 
reduces the cost and time to perform a genome scan. 
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3.6 Data collection methods 
 
In general, the amount of DNA that can be extracted from buccal swabs from dogs is 
small whereas the amount of DNA that can be extracted from whole blood samples is 
much larger. It has also been reported that the quality of the extracted DNA depends 
largely on the method of sampling and the main difference between DNA extracted 
from whole blood and DNA extracted from buccal swabs is the amount of DNA that 
is not from the dog being sampled. It has been reported for humans that the proportion 
of bacterial DNA can exceed 90 % when buccal swabs are being used. Similarly, it 
has been estimated that most of the DNA comes from bacteria present in the dog’s 
oral cavity or from food remnants when a buccal sample is taken too soon after the 
dog has eaten (NEUHAUS et al., 2004). This contamination with bacterial DNA can 
interfere with genetic methods (NEUHAUS et al., 2004). Also, in order to reduce 
time, effort, and material when performing whole genome scans, a multiplex approach 
(e.g., using the MSS-2) should be employed. Using this approach, an exact 
concentration of extracted DNA is required to ensure successful multiplex PCR 
performance (CLARK et al., 2004b). 
 
More specifically, primer pairs of the MSS-2 were specifically designed to allow for 
multiplexing of microsatellite markers for each chromosome, and the primers were 
labeled with different fluorescent dyes (Table 1) based on their location and expected 
product size. The optimal amount of each primer for the multiplexing approach was 
determined by Clark et al. and yielded a total of 70 chromosome-specific panels 
comprising the 327 microsatellite marker of the MSS-2 (CLARK et al., 2004b). PCR 
products obtained by use of a regular PCR-cycler need to be analyzed by 
electrophoretic techniques (e.g., capillary gel electrophoresis on a genetic analyzer) 
against an internal size standard (CLARK et al., 2004b). Standard fragment analysis 
software programs (such as the Genemapper® software) represent a helpful tool for 
evaluating the data. To verify the accuracy of the results and define homozygous and 
heterozygous alleles, this software allows for comparison of genotyping results to the 
published repeats for the MSS-2 (CLARK et al., 2004b). If additional microsatellite 
markers are needed to more closely evaluate a specific region, it is important to 
evaluate these markers with regard to allele appearance and distribution. For example, 
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the genotyping profiles of the canine MSS-2 microsatellite marker DTR13.6 and of 
REN13N11, which is not contained in the MSS-2, in Shar Peis demonstrate different 
homozygous or heterozygous alleles as shown in figures 6 and 7, respectively. The 
calculation of the polymorphic information content (PIC), which provides information 
concerning the informativeness of a marker, is crucial for interpretation of the results. 
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Figure 6: Genotyping peaks for the canine microsatellite marker DTR13.6 from the 
MSS-2. Results for 3 Shar Peis are shown. Panel a) shows a dog that is homozygous 
for DTR13.6 with the allele 356. Panel b) shows a dog that is heterozygous for 
DTR13.6 with alleles 352 and 356. Panel c) shows a dog that is homozygous for 
DTR13.6 with allele 352 (GRÜTZNER et al., 2008). 
 
 
 
 
 
 
 
a b c 
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Figure 7: Genotyping peaks of the canine microsatellite marker REN13N11. This 
marker is not part of the MMS-2. Results for 3 Shar Peis are shown. Panel a) shows a 
dog that is homozygous for REN13N11 with allele 315. Panel b) shows a dog that is 
heterozygous for REN13N11 with alleles 313 and 315. Panel c) shows a dog that is 
homozygous for REN13N11 with allele 313 (GRÜTZNER et al., 2008). 
 
 
 
 
 
 
 
a b c 
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3.7 Use of microsatellite markers 
 
For studies where a specific condition such as cobalamin deficiency, is suspected to 
be hereditary and the aim of that study is to identify a locus or loci that cosegregate 
with the disease, performing a genome wide scan using the MSS-2 is considered a 
suitable approach. Microsatellite markers have been used successfully to locate 
mutations in humans with genetic disorders (HOLMES, 1994). More recently, the 327 
microsatellite markers contained in the MSS-2 set have been used to identify genetic 
regions of interest in various canine hereditary diseases (LOWE et al., 2003; CLARK 
et al., 2006; LIPPMANN et al., 2007). Also, linkage disequilibrium analysis has been 
used to evaluate for linkage as this approach allows for the use of small numbers of 
unrelated affected as well as unaffected individuals (NORDBORG und TAVARE, 
2002; NOLTE and TE MEERMAN, 2001; CLARK et al., 2005b). This method has 
also been shown to be effective for studying genetic diseases in purebred dog 
populations (HYUN et al., 2003; SUTTER et al., 2004; CLARK et al., 2005a; 
CLARK et al., 2006; AWANO et al., 2009). 
 
A reasonable approach for linkage analysis is the evaluation of microsatellite markers 
located in close proximity to potential candidate genes. For instance, two 
microsatellite markers have been discovered to be linked to progressive retinal 
atrophy (PRA) in American Eskimo dogs (MOODY et al., 2005). However, that 
particular study focused on selected microsatellite markers located close to candidate 
genes. If the underlying disease process prevents the selection of suitable candidate 
genes, which is commonly the case, a whole genome scan is necessary. As an 
example, the linkage study for dermatomyositis in the Shetland sheepdog was 
performed using a whole genome scan using the MSS-2 (CLARK et al., 2005a). This 
study discovered one microsatellite marker on canine chromosome 35, which showed 
significant linkage to dermatomyositis in the Shetland sheepdog (CLARK et al., 
2005a). A similar approach was utilized in the study of generalized progressive retinal 
atrophy (PRA) in Schapendoes dogs (LIPPMANN et al., 2007) and copper toxicosis 
in Bedlington Terriers (YUZBASIYAN-GURKAN, 1997). 
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4. MYC gene (v-myc myelocytomatosis viral oncogene) 
 
The MYC gene family encodes a group of transcription factors that control cell 
proliferation and differentiation (GRANDORI and EISENMAN, 1997; ATCHLEY 
and FITCH, 1995). Cell proliferation and differentiation are fundamental to growth, 
development, and also evolution. The genes of the MYC gene family are conserved 
on certain chromosomes in both clinically normal and diseased animals, but are 
associated with different binding motifs (MIYOSHI et al., 1991). In cancer patients, 
the physiologic control of cell proliferation has been shown to be altered due to a 
dysregulation of the MYC gene as the result of retroviral transduction and insertional 
mutagenesis, chromosomal translocation, or gene amplification. In turn, such 
dysregulation leads to increased cell proliferation, impaired cell differentiation, and 
the potential induction of a preneoplastic state. Thus, dysregulation of the MYC gene 
may be associated with a variety of malignant neoplasms (COWLEY et al., 1987). 
Based on these findings, products of the MYC gene represent an important 
component of physiologic cellular activity as well as neoplastic transformation. 
 
In one study, the human transcobalamin II gene was shown to contain at least one 
binding site (motif) for the myc protein a product of the MYC gene (REGEC et al., 
1995). The identification of these motifs within the transcobalamin II gene in humans 
may explain the abnormalities of transcobalamin II concentration in patients with a 
variety of different malignant disorders, but especially multiple myeloma and 
lymphoproliferative disease (AREEKUL et al., 1995; VREUGDENHIL et al., 1992; 
KAIKOV et al., 1991). Thus, the increased plasma concentration of transcobalamin II 
in some patients with multiple myeloma could be due to upregulation of transcription 
of this binding protein by the MYC ligand, a nuclear protein that is believed to 
regulate transcription and gene expression (REGEC et al., 1995). 
 
However, this association could not be confirmed in two other publications, where 
transcobalamin II deficiency was seen in the face of a normal total circulating 
cobalamin concentration (SACHER et al., 1983; KAIKOV et al., 1991). Interestingly, 
only one case report in human patients described a congenital transcobalamin II 
deficiency with a low serum cobalamin concentration (CARMEL and 
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RAVINDRANATH, 1984). An explanation for this finding could be that low serum 
cobalamin concentrations were due to abnormalities of other cobalamin-binding 
proteins in the serum. 
 
 
5. Cobalamin deficiency in Chinese Shar Peis and other breeds 
 
5.1 Cobalamin deficiency in Chinese Shar Peis 
 
Subnormal serum cobalamin concentrations in Shar Peis were first documented in 
1991 (WILLIAMS, 1991). In a small group of 26 Shar Peis evaluated, 21 dogs were 
reported to have subnormal serum cobalamin concentrations and in 19 of these dogs 
cobalamin was undetectable in the serum (WILLIAMS, 1991). This study led to the 
hypothesis that Shar Peis have a predilection for cobalamin deficiency. Serum IgA 
concentrations were also measured in this population, but no association of cobalamin 
deficiency and IgA deficiency could be identified (WILLIAMS, 1991). In 2007, 
another study confirmed a high prevalence of cobalamin deficiency in the Shar Pei 
(BISHOP et al., 2007). In this study, about 64 % of serum samples from Shar Peis 
submitted to the Gastrointestinal Laboratory at Texas A&M University between 2002 
and 2006 had a cobalamin concentration below the lower limit of the reference 
interval (i.e., < 249 ng/L) and 38.1 % of those dogs had serum cobalamin 
concentrations below 100 ng/L, the detection limit of the assay (BISHOP et al., 2007). 
Serum cobalamin concentrations were significantly lower in Shar Peis, with a median 
of 149 ng/L, compared to dogs of other breeds (median: 415 ng/L). Also, compared to 
dogs of other breeds, Shar Peis were 7.6 (95 % confidence interval [CI]: 5.4-10.8) 
times more likely to have a serum cobalamin concentration below the lower limit of 
the reference interval (i.e., < 249 ng/L) and were 55.6 times (95 % CI: 37.3-83.1) 
more likely to have an undetectable serum cobalamin concentration (i.e., < 100 ng/L). 
However, there was no statistically significant difference between serum cobalamin 
concentrations in healthy Shar Peis and healthy dogs of other breeds (BISHOP et al., 
2007). These findings suggest that cobalamin deficiency occurs frequently in Shar 
Peis, but it also suggests that not all individuals within this breed are affected. 
 
Literature review 
 
  
38 
 
Often times, cobalamin deficiency in the Shar Pei is associated with clinical signs of 
chronic small intestinal disease (small bowel diarrhea and weight loss), and can also 
be associated with gastrointestinal protein loss (WILLIAMS 1991; PETERSON and 
WILLARD 2003). However, the absorption of dietary vitamin B12 (cobalamin) is 
complex and involves many steps, including gastric release of protein-bound 
cobalamin, intestinal binding to intrinsic factor, intestinal uptake by a carrier-
mediated transport process, intravascular transport, and cellular uptake. It has been 
shown in the human and veterinary literature that cobalamin deficiency can be 
associated with R-binder deficiency (CARMEL et al., 2003), intrinsic factor 
deficiency (SHEVELL and ROSENBLATT 1992), cobalamin malabsorption 
(GRÄSBECK 2006; FYFE et al., 1991a), and disorders of the intracellular cobalamin 
processing. However, cobalamin absorption, transport, or intracellular processing 
have not been studied in detail in cobalamin deficient Shar Peis with clinical signs due 
to cobalamin deficiency. Hence, the diagnostic approach of measuring only serum 
cobalamin concentration may be inadequate in Shar Peis as it is not known whether 
sufficient amounts of cobalamin reach the tissues in these patients. However, 
measurement of the cobalamin concentration in serum is the most commonly used 
screening test for cobalamin deficiency in both human and veterinary patients. 
Evaluation of other biomarkers that are involved in cobalamin metabolism in addition 
to the serum cobalamin concentration may yield a better understanding of cobalamin 
deficiency in Shar Peis. Homocysteine and methylmalonic acid (MMA) 
concentrations in serum, for example, have both been shown to be increased in human 
patients with cobalamin deficiency (MILLER et al., 2009). Measurement of serum 
MMA has also been described in dogs (BERGHOFF et al., 2009) and in cats 
(RUAUX et al., 2009). In both species, an increased serum MMA concentration has 
been observed with a decreasing serum cobalamin concentration. Thus, the combined 
assessment of both serum cobalamin and serum MMA concentrations might yield 
stronger evidence for cobalamin deficiency at the cellular level than the measurement 
of serum cobalamin concentration alone. 
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5.2 Cobalamin deficiency in dogs of other breeds 
 
During the last decade, cobalamin deficiency has also been identified in dogs of other 
breeds than Shar Peis and has been documented in six case reports. For instance, in 
two juvenile Border Collies, a mild anemia, neutropenia, proteinuria, 
hyperammonemia, and methylmalonic aciduria were associated with serum cobalamin 
deficiency (BATTERSBY et al., 2005; MORGAN and MCCONNELL, 1999). Also, a 
Beagle dog was found to have a low serum cobalamin concentration associated with 
anemia, leukopenia, and methylmalonic aciduria (FORDYCE et al., 2000). In another 
study, selective cobalamin malabsorption was described in a group of juvenile 
Australian Shepherd dogs and was associated with vomiting, diarrhea, and seizures 
(BATTERSBY et al., 2005). Also, a family of 17 Giant Schnauzers presenting with 
low serum cobalamin concentrations and methylmalonic aciduria was shown to be 
affected by a selective intestinal cobalamin malabsorption (FYFE et al., 1991a). In 
contrast, a Labrador retriever showing neurological signs was found to have 
methylmalonic aciduria, but this dog did neither have hypocobalaminemia nor 
hyperammonemia (PODELL et al., 1996). Finally, a Maltese with an increased 
urinary methylmalonic acid concentration but a normal concentration of serum 
methylmalonic acid (MMA) presented with hypoglycemia, acidosis, and ketonuria 
after a period of seizures and stupor. Following a subcutaneous cyanocobalamin 
injection and feeding of a low fat diet these clinicopathological findings normalized 
(O’BRIEN et al., 1999). Interestingly, cases of cobalamin deficiency in dogs of other 
breeds have only been reported from North America and the United Kingdom 
possibly due to the availability of an MMA assay in these two countries. Also, the 
clinical pathology findings seen in these breeds were different from those reported in 
Shar Peis and more closely resembled those in human patients with cobalamin 
deficiency. 
 
The family of Giant Schnauzers with a selective intestinal cobalamin malabsorption 
has been shown to be able to serve as a model for cobalamin deficiency in humans 
(FYFE et al., 1991a). In this group of Giant Schnauzers, normal gastrointestinal 
function and ileal morphology suggests a selective defect of cobalamin absorption at 
the receptor level of the ileal enterocytes. Affected puppies showed neutropenia with 
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hypersegmentation, anemia with anisocytosis and poikilocytosis, and megaloblastic 
changes of the bone marrow, but no abnormality of intrinsic factor or transcobalamin 
II function (FYFE et al., 1991a). Interestingly, these findings were similar to the 
megaloblastic anemia, proteinuria, and low serum cobalamin concentrations seen in 
human patients with Imerslund-Gräsbeck syndrome (Gräsbeck, 2006). This syndrome 
in humans is caused by a selective cobalamin malabsorption by enterocytes, and was 
shown to be due to a mutation of the cubilin gene (called: CUBN) (HE et al., 2003; 
HAUCK et al., 2008). Cubilin is a membrane associated protein that is part of the 
receptor for the intrinsic factor-cobalamin complex (KRISTIANSEN et al., 1999). In 
the group of Giant Schnauzers with cobalamin deficiency evaluated, expression of the 
intrinsic factor-cobalamin complex receptors in the apical brush border membrane in 
both the ileal mucosa and the kidneys were demonstrated to be decreased (FYFE et 
al., 1991a). However, there clinicopathologic findings in cobalamin deficient Shar 
Peis and cobalamin deficient dogs of other breeds differ, suggesting that Shar Peis 
have a very unique disorder of cobalamin metabolism. 
 
 
6. Other diseases commonly diagnosed in Chinese Shar Peis 
 
Two other conditions are reported frequently in Shar Peis, Shar Pei fever and 
cutaneous mucinosis. Shar Pei fever, describes an autoimmune syndrome that causes 
periodic flare-ups and is suspected to be hereditary. The second, cutaneous mucinosis, 
is a disorder characterized by the deposition of excessive amounts of mucin in the 
dermis of the skin and occurs primarily in Shar Peis. To date, a possible association 
between Shar Pei fever and/or cutaneous mucinosis and cobalamin deficiency in Shar 
Peis has not been investigated. However, a link between these diseases in a breed 
classified as being rare (the Shar Pei has been ranked 47th by the American Kennel 
Club in 2009) cannot be ruled out (http://www.akc.org/reg/dogreg_stats.cfm; accessed 
June 29th, 2010). 
 
Shar Pei fever has been shown to be associated with renal amyloidosis and failure in 
several studies. The clinical signs of affected Shar Peis included vomiting, anorexia, 
fever, and weight loss (DIBARTOLA et al., 1990; MAY et al., 1992; RIVAS et al., 
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1992; CLEMENTS et al., 1995). Amyloid deposits have been found in different 
tissues such as the liver, spleen, stomach, small intestine, lymph nodes, and the 
pancreas (DIBARTOLA et al., 1990). In contrast, hepatic amyloidosis without any 
evidence of renal involvement was reported in another study (LOEVEN, 1994). A 
syndrome similar to Shar Pei fever has been described in humans and is called 
Familial Mediterranean Fever (RUPIEPER and HELLER 1991). Both diseases, Shar 
Pei fever and Familial Mediterranean Fever, are characterized by an increased serum 
concentration of interleukin 6 (IL-6), an important mediator of fever and the acute 
phase response (BAYKAL et al., 1993; RIVAS et al., 1992). In a study that 
investigated if Shar Pei fever and/or renal amyloidosis are inherited diseases similar to 
Familial Mediterranean Fever in humans, the proportion of affected dogs from 
different litters ranged between 25 % and 50 % when a phenotypically healthy parent 
was bred to an affected dog (RIVAS et al., 1993). Dogs affected with Shar Pei fever 
showed clinical signs such as anorexia and weight loss, which have also been reported 
in cobalamin deficient Shar Peis. However, serum cobalamin concentrations have 
never been reported in dogs with Shar Pei fever. 
 
Cutaneous mucinosis is a skin disorder that is commonly seen in Shar Peis and is 
suspected to be hereditary in this breed (MULLER, 1990; VON BOMHARD and 
KRAFT, 1998). Clinically, cutaneous mucinosis is associated with signs, such as 
localized alopecia, hyperpigmentation and ulceration of the skin, and swollen hind 
limbs (which can extend from the hock to the hip). This condition is usually 
confirmed by skin biopsies (LOPEZ et al., 1999; ZANNA et al., 2008). 
Histopathologic evaluation of biopsies from Shar Peis with cutaneous mucinosis and 
healthy dogs of other breeds revealed an increased involvement of a certain mast cell 
subtype, characterized by an increased production of chymase, in the pathogenesis of 
cutaneous mucinosis (WELLE et al., 1999). Lopez et al. suggested a potential 
association between cutaneous mucinosis and the development of mast cell tumors in 
the Shar Pei (LOPEZ et al., 1999). A more recent study investigated whether the 
concentration of serum hyaluronic acid (also known as hyaluronan), the main 
component of mucin, and the expression of CD44, the major cell surface receptor for 
hyaluronic acid, are associated with cutaneous mucinosis in Shar Peis. Serum 
hyaluronic acid concentrations were shown to be significantly higher in Shar Peis 
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with cutaneous mucinosis than in healthy controls, which suggest that this condition is 
a consequence of a genetic defect involving hyaluronic acid (ZANNA et al., 2008). 
However, the fact that there was no correlation between hyaluronic acid concentration 
in serum and CD44 expression in this study (ZANNA et al., 2008) would indicate a 
defect in the metabolism of hyaluronic acid rather than an abnormality at the level of 
its receptor. About a year after this report, the same investigators reported that 
cutaneous mucinosis in Shar Peis is associated with an increased expression of the 
hyaluronan synthase gene (ZANNA et al., 2009). Interestingly, a higher production of 
cell surface hyaluronan has also been documented on mucosal endothelial cells in 
human patients with inflammatory bowel disease when compared to healthy controls 
(KESSLER et al., 2008). In this context, low serum cobalamin concentration has been 
documented in both human and canine patients with chronic enteropathies such as 
inflammatory bowel disease (YAKUT et al., 2010; ALLENSPACH et al. 2007). 
Therefore, it is reasonable to hypothesize that cutaneous mucinosis in Shar Peis may 
be related to cobalamin deficiency in this breed. 
 
The concentration of serum cobalamin concentration has not been reported in any of 
the above mentioned studies investigating Shar Pei fever and/or cutaneous mucinosis. 
Thus, further studies are necessary to test the hypothesis of a potential association 
between cobalamin deficiency and these other two common diseases in the Shar Pei. 
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1.1 Abstract 
 
Cobalamin deficiency is a common disorder in Chinese Shar Peis (Shar Peis) and is 
thus suspected to be hereditary. The objective of this study was to identify a genomic 
region or locus with the phenotype of cobalamin deficiency in Shar Peis. Serum 
cobalamin concentration were measured, and blood for genomic DNA extraction was 
collected from 14 cobalamin-deficient Shar Peis and 28 Shar Peis with a serum 
cobalamin concentration in the reference range. The 327 microsatellite markers from 
the canine minimal screening set 2 and 4 additional markers were amplified by 
polymerase chain reaction and genotyped by automated capillary electrophoresis. 
Two microsatellite markers, DTR13.6 (P = 1.4 x 10-6) and REN13N11 (P = 1.5 x 10-
5), both on canine chromosome 13, showed evidence of linkage disequilibrium. These 
findings indicate that the region of chromosome 13 near these markers should be 
mapped and closely examined for potential mutations associated with this disease in 
Shar Peis. 
 
 
1.2 Key words 
 
Chinese Shar Peis, cobalamin, linkage, microsatellite 
 
 
1.3 Introduction 
 
Cobalamin (vitamin B12) is a water-soluble vitamin that is synthesized by 
microorganisms and essential for DNA, heme, and fatty acid synthesis and also for 
intermediate metabolism of sulfur-containing amino acids (Hall 1979; Carmel et al. 
2003; Solomon 2007). Cobalamin is absorbed via receptor-mediated endocytosis in 
the brush border of the ileum (Fyfe et al. 2004). Cobalamin is then transcytosed 
through the intestinal epithelial cells and into the bloodstream and transported to 
various cells to act as a cofactor for the functions mentioned above (Fowler 1998; 
Kozyraki et al. 1999; Solomon 2007). Cobalamin is involved in a variety of metabolic 
processes in many tissues, including cell growth (Scalabrino et al. 2000) and 
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peripheral and central nervous system function (Volkov et al. 2006; Scalabrino et al. 
2000). Bone marrow (Fyfe et al. 1991) as well as bones (Tucker et al. 2005) are also 
affected by cobalamin. A variety of gastrointestinal disorders can cause cobalamin 
malabsorption, which will lead to depletion of cellular cobalamin stores and may 
result in malfunction of multiple organ systems (Volkov et al. 2006). 
 
Subnormal serum cobalamin concentrations have been reported anecdotally in 
Chinese Shar Peis (Shar Pei) (Williams 1991; Bishop 2007). Interestingly, over a 4 
year period, 64.0 % of serum samples from Shar Peis that were submitted to the 
Gastrointestinal Laboratory at Texas A&M University for the measurement of serum 
cobalamin concentration had serum cobalamin concentrations below the lower limit 
of the reference range (252 - 908 ng/L) (Bishop et al. 2007). Furthermore, 53 of 139 
(38.1 %) of all submitted serum samples from Shar Peis had serum cobalamin 
concentrations below the detection limit of the assay (Bishop et al. 2007). 
 
The authors hypothesize that in the Shar Pei, cobalamin deficiency is a genetic 
condition. Therefore, the aim of this study was to perform a genome wide scan using 
the canine minimal screening set-2 (MSS-2) to identify a locus or loci that 
cosegregate with cobalamin deficiency. The MMS-2 set is a group of microsatellite 
markers that have been used previously to identify candidate gene regions of interest 
in canine hereditary diseases (Lowe et al. 2003; Clark et al. 2006; Lippmann et al. 
2007). This set of 327 markers provides an average spacing of 9 mega bases (Mb) 
throughout the canine genome (Guyon et al. 2003; Clark et. al. 2004b). In order to 
evaluate linkage, linkage analysis was utilized as this approach allows for the use of 
small numbers of unrelated affected and unaffected individuals (Nordborg and 
Tavare, 2002; Nolte and Te Meerman, 2002; Clark et. al. 2005). This technique has 
previously been shown to be effective for studying genetic diseases in pure bred dog 
populations (Hyun et al. 2003; Sutter et al. 2004; Clark et al. 2005, 2006; Awano et al. 
2008). 
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1.4 Materials and Methods 
 
Sample Collection 
 
Whole blood and serum samples were collected from 42 unrelated Shar Peis over a 4 
year period, from various parts of the United States. The pedigree information was 
evaluated for a minimum of 3 generations whenever possible to ensure that dogs were 
not closely related. The protocol for collection of blood samples from Shar Peis was 
reviewed and approved by the Clinical Research Review Committee at Texas A&M 
University (CRRC# 2007-30). Owners were asked to complete a questionnaire, 
collecting information concerning their dogs, including age, sex, sexual status, health 
status (including current medications and vaccination status), and the history of any 
prior supplementation with cobalamin, either in pure form or as part of a vitamin B 
complex preparation.  Food was withheld from the dogs for at least 12 hours before 
collection of blood samples. Measurements of serum concentrations of cobalamin and 
canine trypsin-like immunoreactivity (cTLI) were performed at the Gastrointestinal 
Laboratory at Texas A&M University. The reference range for serum cobalamin and 
cTLI concentrations have previously been established as 252 - 908 ng/L and 5.7 - 45.2 
µg/L, respectively (Gastrointestinal Laboratory at Texas A&M University; http:// 
www.cvm.tamu.edu /gilab/assays/index.shtml; accessed February 9th, 2009). 
 
The concentrations of serum cobalamin were measured using an automated 
chemiluminescence assay (Immulite®2000, vitamin B12, Siemens Healthcare 
Diagnostics Inc., Deerfield, IL) and serum cTLI was measured using a 
radioimmunoassay (Canine TLI Double Antibody Radioimmunoassay, Siemens 
Healthcare Diagnostics, Deerfield, IL).  The cobalamin assay has a detection limit of 
150 ng/L. Dogs with a serum cobalamin concentration < 150 ng/L were considered to 
be severely cobalamin deficient. In order to avoid including any dogs with mild 
hypocobalaminemia into the control group, Shar Peis with a serum cobalamin 
concentration within the reference range but ≤ 400 ng/L were excluded from the 
control group. A Mann-Whitney test was used to compare the median of age between 
the two groups of Shar Peis. A Fisher’s exact test was used to evaluate whether 
gender status was associated with cobalamin deficiency. All data was tested for 
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normal distribution using the Kolmogorov-Smirnov test. Significance was set at p < 
0.05. 
 
 
Genotyping 
 
Genomic DNA was isolated from whole blood samples using a commercial kit 
(Puregene DNA Isolation Kit, Gentra Systems, Minneapolis, MN). 
Spectrophotometry was used to evaluate purity and quantity of the extracted DNA 
prior to further analysis. The 327 microsatellite markers of the MSS-2 were used for 
the genome scan. PCR primers for these markers and multiplex PCR conditions have 
previously been described (Clark et al. 2004b). PCR was performed using a 
Mastercycler (Eppendorf North America, Westbury, NY) and the PCR products were 
analyzed by capillary gel electrophoresis on a genetic analyzer (ABI Prism 3130x 
Sequencer, Applied Biosystem, Foster City, CA), with an internal size standard 
(GeneScan 500 LIZ, Applied Biosystem, Foster City, CA) as previously described 
(Clark et al. 2004b). Standard fragment analysis software (Genemapper 3.5 software, 
Applied Biosystem, Foster City, CA) was used to evaluate the data. The genotyping 
results were compared with published repeats (Clark et al. 2004b). 
 
Four other stable microsatellite markers, not included in the canine MSS-2 
(REN65A19, RH103480, RH12645, and REN13N11), were chosen to evaluate the 
region around microsatellite marker DTR13.6 on chromosome 13. These additional 
microsatellite markers had their forward primer labeled with a fluorescent dye 
(6FAM, Gene Technologies Lab, College Station, TX) and were amplified and 
genotyped in all 42 enrolled Shar Peis. Information regarding the canine genome was 
obtained from the CanFam2.0 assembly (http://www.ncbi.nlm.nih.gov/genome/ 
guide/dog/index.html; accessed February 9th, 2009). 
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Linkage studies 
 
For each microsatellite marker, the most frequent allele in the group of Shar Peis with 
an undetectable serum cobalamin concentration was identified, and was compared to 
the frequency in Shar Peis with a serum cobalamin concentration above 400 ng/L. A 
Fisher’s exact test was used to evaluate the significance of the association between the 
two variables in a 2×2 contingency table format for single microsatellite markers. 
Evidence of genetic association was defined as a p < 1.6×10-4 using Bonferroni’s 
correction for multiple comparisons. The PIC (polymorphism information content) 
value, which can range from 0.0 (not informative) to 1.0 (very informative) was used 
to determine how informative each of the markers was for the association studies 
(Clark et al. 2004a). For the microsatellite markers that were not part of the canine 
MSS-2, the PIC was calculated from the estimated allelic frequencies in different dog 
breeds (Clark et al. 2004a; Leopoldino and Pena 2003). The PIC value, which can 
range from 0 (not informative) to 1 (very informative) is a measure of heterozygosity 
and therefore, represents a parameter to describe the informativeness of a marker used 
for association studies (Clark et al. 2004a). After the initial genome scan was 
performed, samples from an additional seven Shar Peis were collected. The genotype 
data for these 7 dogs were analyzed only for the two microsatellite markers of interest 
(DTR13.6 and REN13N11). 
 
 
1.5 Results 
 
Serum cobalamin concentrations were measured in 42 unrelated Shar Peis. 
Undetectable serum cobalamin concentrations (< 150 ng/L) were found in 14 of these 
42 dogs (33.3 %) and these 14 dogs were considered to be severely cobalamin 
deficient. Serum cobalamin concentrations in the remaining 28 Shar Peis ranged from 
400-958 ng/L (median: 608 ng/L). The median age of cobalamin deficient Shar Peis 
was 7.0 years (range: 2 to 10 years). The median age of the enrolled Shar Peis with 
serum cobalamin concentrations in the reference range was 4.5 years (range: 2 to 12 
years). There was a statistically significant difference between the median age of the 
two groups (p = 0.0191). The gender distribution of the cobalamin deficient Shar Peis 
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was 6 male and 8 female dogs. Thirteen of the enrolled Shar Peis with normal serum 
cobalamin concentrations were male and 15 were female. There was no significant 
association of sex and cobalamin deficiency (p = 1.000). Serum concentrations for 
canine trypsin-like immunoreactivity (cTLI) in cobalamin deficient Shar Peis enrolled 
were all within the reference range (5.7-45.2 µg/L). A cTLI concentration within the 
reference range rules out exocrine pancreatic insufficiency (EPI) in the dog. This was 
important as EPI has been documented to be a potential cause of cobalamin 
deficiency (Cooper and Rosenblatt 1987; and Simpson et al. 1989). 
 
Three hundred thirteen microsatellite markers of the canine MSS-2 were genotyped 
across all 38 autosomes and sex chromosomes in all 42 dogs (14 Shar Peis with an 
undetectable serum cobalamin concentration and 28 Shar Peis of the control group 
with a serum cobalamin concentration within the reference range). Eight markers of 
the canine MSS-2 could not be amplified. Additionally, six markers of the canine 
MSS-2 could not be consistently genotyped. The amplicons of those 6 microsatellite 
markers showed a broad peak spectrum with non-distinct allele values. 
 
Following the genome-wide scan with the canine MSS-2, only the microsatellite 
marker DTR13.6, located at position 28,175,350 - 28,175,702 on canine chromosome 
13, yielded significant results (Figure 1). PCR product sizes of 340, 341, 352, and 356 
base pairs (bp) were observed. Allele 356 (bp) of this microsatellite marker was seen 
significantly more frequently in Shar Peis with undetectable serum cobalamin 
concentrations (19 of 28 alleles, 67.9 %) than in the Shar Peis of the control group (8 
of 56 alleles, 14.3 %; Table 1). The genotyped alleles of the microsatellite marker 
DTR13.6 are shown in Table 2. A Fisher’s exact test as a single analysis method and 
the Bonferroni correction indicated an association for allele 356 (bp) of DTR13.6 with 
cobalamin deficiency in Shar Peis (p = 1.4×10-6). Four other stable microsatellite 
markers, that are not included in the canine MSS-2, were chosen to evaluate the 
region around microsatellite marker DTR13.6. The canine microsatellite markers 
REN65A19, RH103480, RH12645, and REN13N11 are all located in close proximity 
to microsatellite marker DTR13.6 on chromosome 13 (Figure 2). Of these, 
REN65A19, RH103480, and RH12645, revealed no association with cobalamin 
deficiency in Shar Peis (p = 8.5×10-2, 1.8×10-1, and 1.5×10-1, respectively) based on a 
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Fisher’s exact test with a Bonferroni correction for multiple comparisons. However, 
allele 315 (bp) of microsatellite marker REN13N11, which is located at position 
29,189,076 - 29,189,385 showed a significant association with cobalamin deficiency 
(p = 1.5×10-5) using a Fisher’s exact test and Bonferroni’s correction for multiple 
comparisons. 
 
In fact, 18 of 28 (64.3 %) cobalamin deficient Shar Pei chromosomes carried this 
allele compared to only 9 of 56 Shar Peis of the control group (16.1 %; Table 1). The 
genotyped alleles of the microsatellite marker REN13N11 are shown in Table 2. In 
addition, the p - value for genetic disequilibrium of both microsatellite markers 
DTR13.6 and REN13N11 was computed. An adjusted p - value of 0.01 revealed that 
these two markers form a single haplotype. 
 
To the author’s knowledge, there are no previously published reports regarding 
microsatellite marker REN13N11 in different dog breeds. Consequently, the 
characteristics of this canine microsatellite marker and the frequency of occurrence of 
different alleles were evaluated in Shar Peis and in healthy dogs of other breeds (16 
German Shepherd Dogs (GSD), 16 White Shepherd Dogs (WSD), and 16 Miniature 
Schnauzers). Genotyping of the PCR products of REN13N11 showed the same alleles 
in Shar Peis compared to GSD, WSD, and Miniature Schnauzers, and the alleles 
identified in all dogs were in the same size range (Table 3). The PIC value for the 
canine microsatellite marker REN13N11, calculated based on the alleles obtained for 
the different dog breeds, was 0.79 (Clark et al. 2004a; Leopoldino and Pena 2003). 
Being relatively close to a value of 1.0, this PIC value indicates a sufficient 
polymorphism of the microsatellite marker REN13N11 and thus the usefulness of its 
interpretation in this association study. 
 
A pedigree of a Shar Pei family was investigated with their respective cobalamin 
concentrations and the contributions of the significant allele 356 of microsatellite 
marker DTR13.6 and the significant allele 315 of the microsatellite marker 
REN13N11. We could only obtain samples from the Sire, Dam, and two puppies from 
one of their litters. The male puppy was diagnosed with cobalamin deficiency and was 
homozygous for both significant alleles of the respective microsatellite markers, 
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whereas the female puppy had a normal serum cobalamin concentration and was 
homozygous for a different allele. The two unaffected Shar Pei parents were both 
heterozygous with one significant allele present (Figure 3). The result of this analysis 
would suggest that the cobalamin deficiency in those few Shar Peis may follow an 
autosomal recessive trait. 
 
After completion of the genome scan with the 42 Shar Peis, seven additional Shar 
Peis (4 cobalamin deficient, 3 with a cobalamin concentration of the control group) 
were genotyped for the two microsatellite markers of interest, leading to a further 
decreased p - value  for both DTR13.6 and REN13N11 (7.8×10-7 and 2.09×10-6, 
respectively). 
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Figure 1: This figure represents the respective p - values for all 313 consecutive 
microsatellite markers computed for the genome wide scan. The arrow indicates the 
significant p - value of microsatellite marker DTR13.6 (1.4×10-6), and the dashed line 
defines the level for this study using Bonferroni’s correction. 
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Figure 2: Ideogram of canine chromosome 13. The microsatellite markers 
REN65A19, RH103480, DTR13.6, REN13N11, and RH12645 are shown at their 
location on chromosome 13. Their approximate locations to the respective 
microsatellite marker DTR13.6 are illustrated in mega bases (Mb). 
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Figure 3: Pedigree of a Shar Pei family. This figure shows a pedigree of a sire and 
dam and two puppies from one of their litters, characterizing the contributions of the 
significant allele 356 of microsatellite marker DTR13.6 (A) and the significant allele 
315 of microsatellite marker REN13N11 (B). The allele combination for both 
littermates being homozygous for both significant alleles is shown (female: normal 
serum cobalamin concentration and male: cobalamin deficient). The two unaffected 
Shar Pei parents present with only one of the significant alleles each. 
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DTR13.6 CD Shar Peis Control Shar Peis Σ 
Allele 356 19 8 27 
other Alleles 9 48 57 
Σ 28 56 84 
REN13N11       
Allele 315 18 9 27 
other Alleles 10 47 57 
Σ 28 56 84 
 
Table 1. Observations for alleles 356 bp and 315 bp for microsatellite markers 
DTR13.6 and REN13N11, respectively, in cobalamin deficient (CD) Shar Peis and 
control Shar Peis (p values of 1.4×10-6 and 1.5×10-5, respectively). 
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DTR13.6 Alleles CD Shar Peis Control Shar Peis 
Homozygous 356 / 356 7 1 
Heterozygous 352 / 356 5 5 
Heterozygous 340 / 356   1 
Homozygous 352 / 352 2 15 
Heterozygous 340 / 352   5 
Homozygous 340 / 340   1 
 Σ 14 28 
    
REN13N11 Alleles CD Shar Peis Control Shar Peis 
Homozygous 315 / 315 6 1 
Heterozygous 313 / 315 6 6 
Heterozygous 315 / 317   1 
Homozygous 313 / 313 2 18 
Heterozygous 307 / 313   1 
Heterozygous 305 / 313   1 
 Σ 14 28 
 
Table 2. Genotyped alleles of the two significant microsatellite markers (with the 
observations for all alleles of DTR13.6 and REN13N11, respectively) in cobalamin 
deficient (CD) Shar Peis and control Shar Peis. 
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 Observed Alleles (bp) Allele Frequency 
Miniature 311  43.8% (14/32) 
Schnauzer 301  43.8% (14/32) 
 307    9.3%   (3/32) 
 303    3.1%   (1/32) 
White  309  56.3% (18/32) 
Shepherd Dog 307  25.0%   (8/32) 
 305    9.3%   (3/32) 
 303    6.3%   (2/32) 
 301    3.1%   (1/32) 
German  307  56.3% (18/32) 
Shepherd Dog 309  40.7% (13/32) 
 305    3.1%   (1/32) 
Chinese Shar 313  65.5% (55/84) 
Pei 315  32.1% (27/84) 
 317    1.2%   (1/84) 
 307    1.2%   (1/84) 
 
Table 3. This table shows the observed alleles for microsatellite marker REN13N11 
and their respective frequencies in four different dog breeds. 
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1.6 Discussion 
 
Inherited disorders of cobalamin metabolism in humans may affect absorption, 
transport, or cellular uptake of cobalamin (Fowler 1998). Humans with juvenile 
cobalamin deficiency were found to have a mutation of the gene encoding intrinsic 
factor (Tanner et al. 2005). Another group of human patients showed mutations of the 
cubilin and amnionless genes, leading to Imerslund-Gräsbeck syndrome (Hauck et al. 
2008; He et al., 2005). These two genes code for proteins that form the cubam 
receptor, which is located on the brush border membrane of the ileal epithelial cells, 
and they are jointly responsible for endocytosis of the intrinsic factor-cobalamin 
complexes (Kozyraki et al. 1999; Fyfe et al. 2004). The various effects of cobalamin 
deficiency are ultimately due to deficient action of the two main cobalamin-requiring 
enzymes, methylmalonyl-CoA mutase and methionine synthase (Fowler 1998). 
 
In dogs, a selective intestinal cobalamin malabsorption has been reported in a family 
of Giant Schnauzers (Fyfe et al. 1991). This syndrome is similar to Imerslund-
Gräsbeck syndrome (He et al. 2003). Affected puppies show clinical signs between 6 
and 12 weeks of age, including neutropenia with hypersegmentation, anemia with 
anisocytosis, poikilocytosis, and megaloblastic changes of the bone marrow (Fyfe et 
al. 1991). There has also been a case report of anemia due to cobalamin deficiency in 
a Border collie (Battersby et al. 2005; Morgan et al. 1999). The dog was found to 
have erythroblastic anemia and methylmalonic aciduria. Additionally, juvenile 
selective cobalamin malabsorption in Australian Shepherds and Beagles has been 
reported (Battersby et. al 2005; Fordyce et. al.2000). These dogs presented with 
clinical signs of hyperammonemia in one report and hypoglycemia associated with 
vomiting, diarrhea, and seizure activity in another (Fordyce et al. 2000; Battersby et. 
al 2005). 
 
Shar Peis with cobalamin deficiency often present with clinical signs of chronic 
gastrointestinal disease (usually small bowel diarrhea and weight loss), frequently 
with gastrointestinal protein loss. However, this syndrome has not yet been 
extensively characterized in this breed. Unfortunately, all evidence is purely anecdotal 
(Williams 1991; Peterson and Willard 2003; Bishop 2007). Cobalamin deficiency in 
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Shar Peis appears to differ from other cobalamin deficiency syndromes reported in 
dogs (Fyfe et al. 1991; Fordyce et al. 2000) and humans (Carmel et al. 2000) where 
gastrointestinal symptoms have not been described. The lack of the classical signs of 
cobalamin deficiency (Fyfe et al. 1991; Fordyce et al. 2000; Carmel et al. 2000) 
suggests that other mechanisms may be responsible for this condition in Shar Peis, 
such as malabsorption interference or defective transport of cobalamin, and a slow-
onset of cobalamin deficiency may lead to a clinical syndrome causing 
gastrointestinal disease. 
 
The success of linkage studies is crucially dependent on correct assignment of 
phenotypes. In order to prevent false classification of affected dogs, dogs with serum 
cobalamin concentrations in the lower range of the reference range (≤ 400 ng/L) and 
dogs younger than 2 years of age were excluded from the control group. This was 
done because cobalamin deficiency has been mostly characterized in juvenile dogs 
(Fyfe et al. 1991; Fordyce et al. 2000; Battersby et al. 2005) and clinical experience 
(Williams 1991; Peterson and Willard 2003; Bishop 2007) suggests that Shar Peis 
usually do not develop cobalamin deficiency until later on in life. Thus, our goal was 
to exclude any dogs with potentially subclinical or preclinical cobalamin deficiency 
from the control group. This exclusion of young dogs may also explain the 
discrepancy in ages between the two groups. Furthermore, data collected from the 
questionnaires regarding the current health status for each dog also suggested that 
control dogs (> 400 ng/L) enrolled into this study were clinically healthy, which 
provides evidence that cobalamin deficiency in this breed is mainly manifested in 
association with gastrointestinal disease. 
 
The linkage analysis approach uses a nonrandom association of alleles, which allows 
for the use of smaller numbers of affected and unaffected individuals (Nolte and Te 
Meerman 2002; Nordborg and Tavare, 2002). Several veterinary studies have shown 
that even small sample sizes are useful for studying genetic diseases in pure bred dog 
populations (Hyun et al. 2003; Clark et al. 2006; Lippmann et al. 2007; Awano et al. 
2008). As a first step, a genome wide scan can be performed using a relatively small 
number of markers in order to identify regions of association (Sutter et al. 2004) and 
such an approach has been conducted in this study. However, an association is 
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dependent upon the respective population, and linkage disequilibrium can extend 
from 400 to 700 kb in popular breeds (e.g., GSD, Labrador Retriever), whereas it can 
range from 3 to 3.2 Mb in breeds with a smaller population size such as the Chinese 
Shar Pei (Sutter et al. 2004; Guyon 2003). In the United States for instance, Shar Peis 
appear to be a rare breed, ranked 45th by the American Kennel Club in 2008 
(compared to position 3 for the GSD). Therefore, in Shar Peis a potentially affected 
genomic locus, such as a mutant gene, could potentially be identified using the MSS-2 
set and may be located up to 3 Mb up- or down-stream of the respective microsatellite 
marker. 
 
However, this study may not conclusively narrow down the region on chromosome 13 
as the major locus or primary gene responsible for cobalamin deficiency in the Shar 
Pei, because the MSS-2 set contains only 327 microsatellite markers with an average 
marker spacing of 9 Mb, and thus large gaps may be missed. However, not all genes 
that have been associated with cobalamin deficiency in humans or genes encoding for 
cobalamin binding proteins have been identified in the dog (Qureshi et al. 1994; 
Tanner et al. 2005). Therefore, further studies to fine map this region as well as the 
whole genome using a SNP array are warranted. 
 
Allele 356 (bp) of microsatellite marker DTR13.6, which is part of the canine MSS-2, 
was found significantly more frequently in cobalamin-deficient Shar Peis than in Shar 
Peis of the control group. This marker is well characterized in other dog breeds, such 
as the Boykin Spaniel, German Shepherd dog, Shetland Sheepdog, Great Dane, 
Collie, and Havanese. The published PIC for the microsatellite marker DTR13.6 is 
0.65 (Clark et al. 2004b). The PCR product size for this marker ranged from 316 to 
356 bp (316, 336, 340, 344, 348, 352, and 356, respectively) (Clark et al. 2004b). We 
also found an additional canine microsatellite marker (REN13N11) that is not 
included in the canine MSS-2, whose allele 315 (bp) was also significantly associated 
with cobalamin deficiency in Shar Peis. Microsatellite marker REN13N11 was 
evaluated for PCR product size and PIC value. The PIC describes the usefulness of 
genetic markers for linkage studies when attempting to localize the gene locus on the 
chromosome, which may be involved in a rare disease (Guo and Elston 1999). 
Because the PIC values for both canine microsatellite markers that appeared to be 
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associated with cobalamin deficiency in Shar Peis, DTR13.6 and REN13N11, were 
similar, both markers are equally informative. 
 
In this study, we present the first evidence of an association in a region located on 
canine chromosome 13. In this region, there are no previously identified genes 
reported to be associated with cobalamin deficiency in dogs or any other species. 
According to the data that is publicly available on the Ensemble Genome Browser, 
only one gene was identified near the region of the two microsatellite markers on 
canine chromosome 13. This gene, MYC_CANFA, is located between the two 
microsatellite markers that showed linkage disequilibrium, which is located 
approximately 0.06 Mb from microsatellite marker DTR13.6 and 1.01 Mb from 
REN12N11. Regec et al. (1995) have shown that the human transcobalamin II gene 
contains at least one binding motif for transacting oncogene products such as c-myc 
protein, the product of the MYC_CANFA gene. Hence, further investigation is 
warranted to determine whether the MYC_CANFA gene represents a potential 
candidate gene for cobalamin deficiency in Shar Peis. 
 
In summary, we present evidence for an association of canine microsatellite markers 
DTR13.6 and REN13N11, located on chromosome 13, with cobalamin deficiency in 
Chinese Shar Peis. The future aim is to utilize a finer mapping tool, such as single 
nucleotide polymorphisms (SNP), to both verify and to fine map this region that is 
associated with this syndrome in the Shar Pei to locate candidate genes for further 
investigation. 
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IV Discussion 
 
In this association study, serum cobalamin, folate, and cTLI concentrations were 
evaluated in Shar Peis. Fourteen of the enrolled Shar Peis had an undetectable serum 
cobalamin concentration. The median serum cobalamin concentration of the 28 Shar 
Peis with a normal serum cobalamin concentration that were enrolled was 614.5 ng/L 
and was similar to the median previously reported for 20 healthy Shar Peis (529.6 
ng/L) and 61 healthy dogs of other breeds (500.7 ng/L) (BISHOP et al., 2007). 
Similar to a previous study, serum folate concentrations in cobalamin-deficient Shar 
Peis (median: 11.2 µg/L) were not significantly different from those in Shar Peis with 
normal serum cobalamin concentrations (median: 11.9 µg/L; p - value: 0.650) 
(unpublished data and BISHOP et al., 2007). Serum cTLI concentrations in all dogs of 
both groups (cobalamin-deficient Shar Peis and Shar Peis with normal serum 
cobalamin concentrations) were within the reference interval for the assay. However, 
compared to Shar Peis with normal serum cobalamin concentrations, cobalamin-
deficient Shar Peis showed significantly higher serum cTLI concentrations (medians: 
12.3 µg/L and 19.1 µg/L, respectively; p - value: < 0.010; unpublished data). The 
reason for this finding is not clear and would require further studies of exocrine 
pancreatic function and pathology in Shar Peis, including pancreatic histopathology in 
dogs from both groups. However, both medians were within the limits of the 
reference interval for serum cTLI concentrations and thus this finding does not appear 
to be of any clinical relevance. 
 
The genetic portion of this study was to identify a genomic region or locus that 
cosegregates with the phenotype of cobalamin deficiency in Shar Peis. It is generally 
accepted that the success of genetic linkage studies is dependent on the correct 
assignment of phenotypes. In order to prevent an erroneous classification of affected 
dogs, dogs with serum cobalamin concentrations in the lower range of the reference 
interval (i.e., < 400 ng/L) and dogs less than 2 years of age were excluded as controls. 
Also, the data collected from questionnaires regarding the current health status of 
each dog suggested that all dogs enrolled into this association study were clinically 
and thus phenotypically stable. 
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In this association study, allele 356 (bp) of the canine MSS-2 microsatellite marker 
DTR13.6 was found significantly more frequently in cobalamin-deficient Shar Peis 
than in Shar Peis with a normal serum cobalamin concentration. This marker is well 
characterized in other dog breeds, such as the Boykin Spaniel, German Shepherd dog, 
Shetland Sheepdog, Great Dane, Collie, and Havanese. The published PIC of the 
microsatellite marker DTR13.6 is 0.65 (CLARK et al., 2004). The PCR product sizes 
for this marker range from 316 to 356 bp (316, 336, 340, 344, 348, 352, and 356 bp, 
respectively) in different dog breeds (CLARK et al., 2004). We found an additional 
canine microsatellite marker (REN13N11, not included in the canine MSS-2), for 
which allele 315 (bp) was also significantly associated with cobalamin deficiency in 
Shar Peis. Microsatellite marker REN13N11 was evaluated for PCR product size and 
revealed a PIC value of 0.79. Because the PIC values of both canine microsatellite 
markers co-segregating with cobalamin deficiency in Shar Peis, DTR13.6 and 
REN13N11, are comparable, both markers are considered equally genetically 
informative. This study in Shar Peis identified a critical region on canine chromosome 
13 that was associated with cobalamin deficiency, but does not contain any of the 
genes previously reported to be associated with cobalamin deficiency in dogs or any 
other species. 
 
The genomic map of a comprehensive database was used to identify genes that are 
located in close proximity to these two microsatellite markers located on canine 
chromosome 13, and revealed only one gene, the MYC_CANFA gene at location 
28,240,103 - 28,242,545 with a distance of approximately 0.06 Mb to the 
microsatellite marker DTR13.6. In humans, mutations of this gene have been 
proposed as a cause of abnormal plasma transcobalamin II concentrations in some 
patients with malignant disorders and lymphoproliferative diseases, which are 
believed to be a product of the over expressed myc gene (REGEC et al., 1995). It is 
interesting to note that there appears to be a homology of portions of this gene and the 
human transcobalamin II gene (REGEC et al., 1995). In general, past studies have 
reported consistently normal serum cobalamin concentrations in human patients with 
transcobalamin II deficiency (FOWLER, 1998; QURESHI et al., 1994). However, a 
single case report of congenital transcobalamin II deficiency in a human patient was 
associated with a low serum cobalamin concentration (CARMEL and 
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RAVINDRANATH, 1984). A possible explanation for this finding could be that the 
subnormal serum cobalamin concentration reflects abnormalities of other serum 
cobalamin-binding proteins such as the R-binder. Because it is well known that 
endogenous cobalamin is usually carried by R-binders and not by transcobalamin II 
(HALL, 1977), normal serum cobalamin concentrations are to be expected in this 
condition. Also, this patient had no methylmalonic aciduria, which has been shown a 
typical consequence of congenital transcobalamin II deficiency (HALL, 1981). The 
finding of this case report illustrates that transcobalamin II deficiency in humans is 
more complex than merely a lack of transcobalamin II. The MYC_CANFA gene was 
sequenced in three Shar Peis with cobalamin deficiency and three Shar Peis with a 
normal serum cobalamin concentration (GRÜTZNER et al., 2008). No differences in 
the DNA sequences of the MYC_CANFA gene were identified when compared 
between the published canine sequence, the cDNA sequence, and between both 
groups of Shar Peis (GRÜTZNER et al., 2008). Thus, this study suggests that 
cobalamin deficiency in Shar Peis is not associated with a mutation of the 
MYC_CANFA gene (GRÜTZNER et al., 2008). However, there might be an 
additional exon of the MYC_CANFA gene in dogs, which has also been described in 
humans and cats, which might carry a mutation (MIYAMOTO et al., 2000). 
 
Despite there being 327 microsatellite markers in the canine MSS-2, the average 
microsatellite marker spacing is 9 Mb (with no gaps larger than 17.1 Mb) (CLARK et 
al., 2004). Due to those gaps between the microsatellite markers it is possible that an 
entirely different area or single genes on the canine genome are associated with 
cobalamin deficiency in Shar Peis. Also, genes encoding for cobalamin-binding 
proteins and the regions around published genes have not been definitively elucidates 
in dogs as of yet. Thus it remains unknown whether the locus on canine chromosome 
13 represents a major locus for cobalamin deficiency in this breed. A future aim could 
be to utilize a more detailed mapping tool, such as screening for single nucleotide 
polymorphisms (SNP), to both verify and to fine map this region that is associated 
with this syndrome in the Shar Pei as well as locate candidate genes for further 
investigation. 
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Cobalamin has been shown to be involved in many enzymatic reactions by 
mammalian cells (CARMEL et al., 2003). Both human and veterinary studies have 
suggested that an increased serum methylmalonic acid concentration reflects 
cobalamin deficiency at the cellular level (RUAUX et al., 2009; BERGHOFF et al., 
2009). A combination of the measurement of serum cobalamin and serum 
methylmalonic acid concentration might therefore be considered to be stronger 
evidence of cobalamin deficiency at the cellular level than a decreased serum 
cobalamin concentration alone. This, a phenotypic re-classification based on serum 
cobalamin and methylmalonic acid concentrations may lead to identification of a 
different region on chromosome 13 or even on a different chromosome. 
 
Two other conditions have been reported to occur frequently in this breed, Shar Pei 
fever and cutaneous mucinosis. Shar Pei fever is an autoimmune disorder causing 
periodic flare-ups of fever. Cutaneous mucinosis is characterized by the deposition of 
excessive amounts of mucin in the dermis. Hyaluronic acid is the main component of 
mucin and its concentration was shown to be significantly higher in serum samples 
from Shar Peis with cutaneous mucinosis than in healthy controls. However, to date, a 
possible association between Shar Pei fever and/or cutaneous mucinosis and 
cobalamin deficiency has not been investigated in Shar Peis. Thus, further studies to 
evaluate a possible connection between these conditions are needed. A logical first 
step would be to investigate serum cobalamin and methylmalonic acid concentrations 
in patients with Shar Pei fever and cutaneous mucinosis. 
 
In summary, the association of cobalamin deficiency in Shar Peis with alleles 356 
(bp) and 315 (bp) of the canine microsatellite markers DTR13.6 and REN13N11, 
respectively, will facilitate further evaluation of the genomic loci in close proximity to 
both of these microsatellite markers on canine chromosome 13. Also, the data suggest 
that cobalamin deficiency in Shar Peis is not associated with a mutation of the 
MYC_CANFA gene. However, a phenotypic re-classification based on serum 
methylmalonic acid concentrations may lead to the identification of a different region 
of canine chromosome 13 or even on a different chromosome. 
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V Summary 
 
Cobalamin (vitamin B12) deficiency is a common disorder in the Chinese Shar Pei 
(Shar Pei), although the severity of clinical sings and the age of onset vary widely. 
Cobalamin deficiency in the Shar Pei is suspected to be hereditary. Therefore, the 
objective of this study was to investigate a potential genetic linkage of microsatellite 
markers to cobalamin deficiency in Shar Peis. Whole blood and serum samples were 
collected from a total of 42 unrelated Shar Peis. Serum cobalamin concentration was 
measured for each dog and genomic DNA was extracted from whole blood. The 327 
microsatellite markers from the canine minimal screening set-2 (MSS-2) and four 
additional canine microsatellite markers not contained in the MSS-2, were amplified 
by polymerase chain reaction (PCR). The PCR products were resolved by automated 
capillary electrophoresis, and sized relative to an internal standard followed by 
analysis of genotype data using a commercially available software package. Linkage 
analysis was conducted by use of a Fisher’s exact test, and statistical significance was 
set at p < 1×10-4. 
 
Undetectable serum cobalamin concentrations (< 150 ng/L) were observed in 14 of 42 
dogs (33.3 %) and these dogs were considered to be severely cobalamin deficient. 
Serum cobalamin concentrations were within the reference range in the remaining 28 
dogs. Allele 356 of the microsatellite marker DTR13.6 on chromosome 13 was found 
significantly more frequently in cobalamin-deficient Shar Peis (19 of 28 alleles, or 
67.9 %) than in Shar Peis with a serum cobalamin concentration in the reference 
interval (10 of 56 alleles, or 17.9 %; p = 8×10-6). Allele 315 of microsatellite 
REN13N11 on chromosome 13, which is not part of the MSS-2, was also found 
significantly more frequently in cobalamin-deficient Shar Peis (18 of 28 alleles, or 
64.3 %) than in Shar Peis with a normal serum cobalamin concentration (10 of 56 
alleles, or 17.9 %; p = 3×10-5). The genomic map of a comprehensive database was 
used to identify genes that are located in close proximity to these two microsatellite 
markers on canine chromosome 13, and revealed only one gene, the MYC_CANFA 
gene, at location 28,240,103 - 28,242,545 with a distance of approximately 0.06 Mb 
to the microsatellite marker DTR13.6. Primers for the MYC_CANFA gene were 
chosen to amplify exons I and II, respectively. The DNA sequencing results were 
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compared between three cobalamin-deficient Shar Peis, three Shar Peis with a normal 
serum cobalamin concentration, and also with the published cDNA sequences as part 
of the Ensemble Genomic map. No difference in the entire DNA sequence of the 
MYC_CANFA gene was found between any of the dogs belonging to either of the 
two groups, as well as the published canine sequence or the cDNA sequence. 
 
Two microsatellite markers on canine chromosome 13, DTR13.6 and REN13N11, 
showed significant evidence of linkage to serum cobalamin deficiency in Shar Peis. 
Also, cobalamin deficiency in Shar Peis does not appear to be associated with a 
mutation of the MYC_CANFA gene. Further studies are warranted to investigate 
other genomic loci in proximity to these microsatellite markers on canine 
chromosome 13 for possible mutations in Shar Peis with cobalamin deficiency. 
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VI Zusammenfassung 
 
Cobalaminmangel (vitamin B12-Mangel) stellt eine beim Chinesischen Shar-Pei 
(Shar-Pei) häufig vorkommende Erkrankung dar, wobei das Ausmaß der klinischen 
Symptomatik sowie das erstmalige Auftreten des Cobalaminmangels beträchtlich 
variieren. Dem Cobalaminmangel beim Shar-Pei wird eine hereditäre Komponente 
zugeschrieben. Daher bestand das Ziel dieser Studie in der Identifikation der 
genetischen Verknüpfung zwischen Allelen von Microsatellitenmarkern und einem 
Cobalaminmangel beim Shar-Pei. Vollblut- und Serumproben wurden von insgesamt 
42 nicht miteinander verwandten Shar-Peis gesammelt. Für jeden in die Studie 
einbezogenen Hund wurde die Serumkonzentration von Cobalamin bestimmt und die 
Vollblutprobe zur Extraktion von DNA verwendet. Die 327 Microsatellitenmarker des  
caninen Minimal Screening Set-2 (MSS-2), sowie vier der nicht im MSS-2 
enthaltenen Microsatellitenmarker, wurden mit Hilfe der Polymerasekettenreaktion 
(PCR) amplifiziert. Die PCR-Produkte wurden anschließend anhand automatischer 
Kapillarelektrophorese sowie eines internen Standards ihrer Größe nach aufgetrennt, 
und mit Hilfe einer kommerziell verfügbaren Software analysiert. Die statistische 
Auswertung erfolgte anhand des Vierfeldertests nach Fisher, wobei die statistische 
Signifikanzgrenze mit p < 1×10-4 festgelegt wurde. 
 
Vierzehn der 42 Shar-Peis (33,3 %) wiesen keine messbare Konzentration von 
Cobalamin im Serum (< 150 ng/L) auf und wurden daher der Gruppe von Hunden mit 
schwerem Cobalaminmangel zugeordnet. Bei den verbleibenden 28 Hunden lag die 
Serumkonzentration von Cobalamin innerhalb des Referenzintervals. Allel 356 (bp) 
des auf Chromosom 13 befindlichen Microsatellitenmarkers DTR13.6 wies einen 
signifikanten Unterschied in der Verteilung zwischen Shar-Peis mit Cobalaminmangel 
(19 von 28 Allelen oder 67,9 %) und Shar-Peis mit einer physiologischen 
Serumkonzentration von Cobalamin auf (10 von 56 Allelen oder 17,9 %; p = 8×10-6). 
Für Allel 315 des ebenfalls auf Chromosom 13 befindlichen Microsatellitenmarkers 
REN13N11 ergab sich ebenso ein signifikanter Unterschied in der Verteilung 
zwischen Shar-Peis mit Cobalaminmangel (18 von 28 Allelen, oder 64,3 %) und Shar-
Peis mit physiologischer Cobalaminkonzentration im Serum (10 von 56 Allelen, oder 
17,9 %; p = 3×10-5). Anhand einer genetischen Datenbank ließ sich nur ein einziges 
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Gen in der Nähe dieser beiden Microsatellitenmarker auf Chromosom 13 ausmachen. 
Dieses Gen, MYC_CANFA, befindet sich etwa 0.06 Mb vom Microsatellitenmarker 
DTR13.6 entfernt in Position 28,240,103 - 28,242,545. Im Anschluss an die Auswahl 
von Primern für die zwei bekannten Exons des MYC_CANFA Gens wurden diese 
beiden Exons sequenziert. Die Resultate der DNA-Sequenzierung wurden 
anschließend zwischen Shar-Peis mit Cobalaminmangel und solchen mit normaler 
Serumcobalaminkonzentration sowie mit in Datenbanken publizierten DNA-
Sequenzen verglichen. Hinsichtlich der DNA-Sequenzen des MYC_CANFA-Gens 
beider Shar-Pei Gruppen, sowie der für den Hund publizierten DNA-Sequenz, als 
auch der cDNA-Sequenz waren jedoch keine signifikanten Unterschiede festzustellen. 
 
Für die auf Chromosom 13 befindlichen Microsatellitenmarker DTR13.6 und 
REN13N11 bestand ein signifikanter Zusammenhang mit dem Cobalaminmangel 
beim Shar-Pei. Zudem scheint der Cobalaminmangel beim Shar-Pei nicht mit 
Veränderungen auf dem MYC_CANFA-Gen verbunden zu sein. Weitere Studien zum 
Cobalaminmangel beim Shar-Pei sind nötig, um genetische Loci in unmittelbarer 
Nähe dieser beiden Microsatellitenmarker auf Chromosom 13 näher zu untersuchen. 
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VIII  Table and figure legends 
 
Figure 1: Comparison of serum cobalamin concentration in dogs    4 
of different breeds 
 
Figure 2: Chemical structure of cobalamin       6 
 
Figure 3: Cobalamin co-factor: methionine synthase    12 
 
Figure 4: Cobalamin co-factor: methylmalonyl-CoA mutase   13 
 
Figure 5: Cobalamin deficiency: increased methylmalonic acid  18 
 
Table 1: Chromosome-specific microsatellite multiplex set (MSS-2)        26-28 
 
Figure 6: Genotyping peaks of the microsatellite marker DTR13.6 of  33 
Chinese Shar Peis 
 
Figure 7: Genotyping peaks of the microsatellite marker REN13N11 of 34 
Chinese Shar Peis 
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Association Study of cobalamin deficiency in the Chinese Shar Pei 
 
Figure 1: Computed p - values of the genome wide scan   52 
 
Figure 2: Ideogram of canine chromosome 13     53 
 
Figure 3: Pedigree of a Shar Pei family      54 
 
Table 1: Allele observations for DTR13.6 and REN13N11 in   55 
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cobalamin deficient Shar Peis and control Shar Peis 
 
Table 2: All genotyped alleles for DTR13.6 and REN13N11 in   56 
cobalamin deficient Shar Peis and control Shar Peis 
 
Table 3: Observed alleles for microsatellite marker REN13N11 and   57 
their respective frequencies in four different dog breeds 
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